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THIRD AMENDED COMPLAINT
I.

SUMMARY

1. The States and Commonwealths of New York, Michigan, Alabama, Alaska, Arizona,
Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois,
Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota,
Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico,
North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island,
South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia,
Wisconsin, and Wyoming by and through their Attorneys General, and the District of Columbia, by and
through its Corporation Counsel, (collectively "Plaintiff States" or "States") bring this action in their
proprietaiy capacities on behalf of departments, bureaus, and agencies of state government as injured
purchasers or reimbursers; and as parens patriae on behalf of natural persons in their collective States,
and/or in those Plaintiff States where class actions may be brought, pursuant to Rules 23(a) and (b) of
the Federal Rules o f Civil Procedure, on behalf of all natural persons residing in the Plaintiff States not
otherwise represented by the Plaintiff States as parens patriae , and their respective States' quasi
sovereign interests in fair competition and the health of their citizenry, and/or in their sovereign
capacities; against Defendants Aventis S A., successor in interest to Hoechst Aktiengesellschaft
("Hoechst A.G."), Aventis Pharmaceuticals Inc. ("Aventis"), formerly known as Hoechst Marion
Roussel, Inc. ("HMRI"); its subsidiary Carderm Capital, L.P. ("Carderm"); and Andrx Corporation
("Andrx"). (Collectively "Defendants".)
2. This action seeks relief for a series o f anti-competitive and illegal acts, by which Defendants
sought to delay or prevent the marketing of less expensive, generic alternatives to Cardizem CD, a
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highly profitable, brand-name drug for treatment of chronic chest pains and high blood pressure, and
prevention o f heart attacks.
3. On September 15, 1997, Defendant Andrx gained preliminary Food and Drug
Administration ("FDA") approval for a generic version o f Cardizem CD. Such preliminary approval
would have enabled Andrx to enter the market with Cartia XT, its generic version of Cardizem CD, as
o f July 9, 1998. Instead, on September 24, 1997, Andrx entered into a Stipulation and Agreement
with HMRI (the "Agreement"), under which HMRI agreed to make quarterly payments of millions of
dollars in return for Andrx's agreement to keep its generic version of Cardizem CD off the market, and
to retrain from selling any other drug that was the bioequivalent of Cardizem CD. Further, the
Agreement required Andrx to maintain the application it had pending before the FDA at the same time it
withheld its product, the effect of which was to keep other potential generic competitors from the
market. As a result of this Agreement, HMRI paid Andrx nearly $90 million and in exchange, Andrx
delayed the marketing of Cartia XT for nearly a year. The market entry of other generic drugs was also
obstructed and consumers were deprived of lower-priced alternatives to Cardizem CD.
4, The Agreement between HMRI and Andrx was only one manifestation of a systematic
effort by HMRI to obstruct the market entry of competitors to Cardizem CD. HMRI also sought to
prevent another drug manufacturer, Biovail Corporation ("Biovail"), from selling its own generic
alternative to Cardizem CD. HMRI did so by reneging on a commitment to provide Biovail with the
right to use data crucial to securing speedy FDA approval of its drug. On or about July 7,1997, shortly
before it concluded its agreement with Andrx, HMRI offered to pay Biovail to delay its sale of a generic
version of Cardizem CD. This offer to Biovail was strikingly similar to the agreement that Hoechst and
Andrx entered to delay generic competition.
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5. The Defendants' allocation of the market for Cardizem CD and its bioequivalents
constituted an unreasonable restraint o f trade and a violation o f the Sherman Act. Moreover, by means
o f the Agreement and other anti-competitive acts, HMRI engaged in a conspiracy to extend its
statutorily granted monopoly on Cardizem CD beyond its proper expiration, and did in fact illegally
maintain its monopoly on the market for Cardizem CD and its bioequivalents. Alternatively, by means
o f the Agreement and other anti-competitive acts, HMRI engaged in a conspiracy to extend its
monopoly on once-a-day extended release diltiazem prescription drugs, and did in fact illegally maintain
its monopoly on the market for once-a-day extended release diltiazem prescription drugs.
6. A sa result of this illegal conduct, Plaintiff States, and natural persons residing therein, were
deprived o f equally effective, cheaper generic alternatives to Cardizem CD, and instead were forced to
pay the monopoly price charged by HMRI for its brand-name drug. These actions deprived Plaintiff
States and their consumers o f a free and fair market for pharmaceutical products, were detrimental to
the health o f those citizens who could not afford to pay the higher prices charged by HMRI, and
resulted in higher costs to government and other payers o f healthcare expenses.
7. By this action, the States seek: 1) monetary relief to remedy and compensate them, and
consumers residing therein, for the injuries they sustained as a result of Defendants' anti-competitive
acts; and 2) equitable relief and civil penalties, including disgorgement o f profits, to prevent Defendants
from engaging in similar improper conduct in the future, and to restore the integrity of the marketplace.
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II.

JURISDICTION AND VENUE

8. This Complaint, which alleges violations of Sections 1 and 2 of the Sherman Act, 15 U.S.C.
§§ 1 and 2, is filed under, and jurisdiction is conferred upon this Court by, Section 4 of the Clayton Act,
15 U.S.C. § 15, and Section 16 o f the Clayton Act, 15 U.S.C. § 26.
9. The Complaint also alleges violations of state antitrust, unfair competition and/or consumer
protection statutes and related state laws. This Court has jurisdiction over those claims under 28
U.S.C. § 1367, and under the principles of supplemental jurisdiction. The federal and state law claims
arise from a common nucleus of operative facts, and the entire suit commenced by this Complaint
constitutes a single action which would ordinarily be tried in one judicial proceeding. The exercise of
supplemental jurisdiction would avoid duplication and a multiplicity of actions, and should be exercised
in the interests of judicial economy, convenience and fairness.
10. Venue in this district is proper under Section 12 of the Clayton Act, 15 U.S.C. § 22 and 28
U.S.C. § 1391(b) and (c). At all times relevant to this action, Defendants transacted business, did
business, or were found in the Eastern District of Michigan. The claims alleged also arose, in part, in
this judicial district.

III.

11.

THE PARTIES

The States, by and through their Attorneys General, bring this action in their proprietary

capacities on behalf o f departments, bureaus, and agencies of state government as injured purchasers or
reimbursers under Medicaid and other programs; as parens patriae on behalf of natural persons in their
collective States and/or in those Plaintiff States where class actions may be brought, pursuant to Rules
23(a) and (b) of the Federal Rules o f Civil Procedure, on behalf of all natural persons residing in the
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Plaintiff States not otherwise represented by the Plaintiff States as parens patriae , who purchased
Cardizem CD and/or its AB3 rated bioequivalents from January 1, 1998, through a date found to be
appropriate by the Court; and on behalf of their respective States' quasi-sovereign interests in fair
competition and the health of their citizemy and/or in their sovereign capacities.
12. Defendant Aventis S.A. is a French corporation with its office and principal place o f
business in Strasbourg, France. Aventis S.A. was formed in December 1999, following the merger of
Hoechst A.G., a German corporation, and Rhone-Poulenc, S.A, a French corporation.
13. Defendant Hoechst A.G. is a corporation formed in the Federal Republic of Germany with
its principal place of business in Frankfurt, Germany. In December 1999, Hoechst A.G. and RhonePoulenc, S.A. a French corporation, merged to form Aventis S.A. a French corporation. Hoechst A.G.
continues to operate as an affiliate of Aventis S.A. and approximately 97% of the shares of Hoechst
A.G. are held by Aventis S.A. with the remaining 3% held by private and institutional shareholders.
Hoechst A.G. is listed on the Frankfurt Stock Exchange.
14. Defendant Aventis Pharmaceuticals Inc. is a Delaware corporation with its office and
principal place o f business in Parsippany, New Jersey ("Aventis"). Aventis is an indirect, wholly owned
subsidiary of Aventis S.A. Until the merger of Hoechst A.G. and Rhone-Poulenc, S.A., Aventis was
known as HMRI, which was an indirect, wholly owned subsidiary o f Hoechst A.G. Aventis is, and
HMRI was, responsible for, among other things, developing, distributing, advertising and selling
Cardizem CD throughout the United States. On information and belief, Aventis does business
throughout the United States, and is the successor in interest to HMRI in all respects.
15. Defendant Cardeim Capital L.P. ("Carderm") is a Delaware limited partnership having its
office and principal place of business at Richmond House, 12 Par-la-Ville Road, Hamilton, Bermuda.
Carderm was directly or indirectly owned or controlled by HMRI. On information and belief, Carderm
is now directly or indirecdy owned or controlled by Aventis. Carderm holds the patents covering
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Cardizem CD and licensed them to HMRI. On information and belief, the patents on Cardizem CD
held by Carderm are now licensed to Aventis.
16. Defendant Andrx Corporation is a Delaware corporation with its office and principal place
of business at 4001 S.W. 47th Avenue, Fort Lauderdale, Florida 33314. Andrx develops,
manufactures and markets controlled-release drugs. Andrx does business throughout the United States
through its distribution subsidiary, Anda Generics, which sells generic drugs to independent pharmacies
and regional drug chains. Andrx developed a generic bioequivalent of Cardizem CD, called Cartia XT,
which was tully approved by the FDA for sale in the United States in June 1999.

IV.

A.

ANTICOMPETITIVE CONDUCT

The Stamtnry Regime fnr Entry of Generic. Drugs

17. A generic drug is a pharmaceutical product comparable to a brand-name drug in dosage,
form, strength, route of administration, quality, performance characteristics and intended use. It is
typically sold, however, at a substantial discount from the brand-name drug's price. Where a generic
drug is completely equivalent to a pioneer or brand-name drug, the FDA assigns the generic drug an AB
rating.
18. Cardizem CD is available in the United States only by prescription written by a physician.
When a prescription is written for a brand-name drug such as Cardizem, a pharmacist can fill the
prescription only by dispensing either the brand-name drug or its AB rated generic.
19. Under most insurance plans, a pharmacist will substitute an AB rated generic version of a
prescribed brand-name drug, when available, unless the physician has indicated "DAW" or "dispense as
written" on the prescription. Similarly, many State agencies for which Plaintiffs seek to recover
damages and other monetary relief have policies or practices which allow, or require, that they purchase
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cheaper, bio equivalent, generic alternatives to brand-name drugs when they are available, or set a
maximum allowable cost ("MAC") price which reflects the less expensive generic product prices.
20. In order for Cardizem CD or its generic equivalent products to be eligible for utilization
under state Medicaid programs, the manufacturer must enter a rebate agreement either directly with the
State or with the United States Secretary of Health and Human Services, acting on behalf of the State.
HMRI has entered such a contract which, upon information and belief, is substantially similar in form to
the contract attached as Appendix A.
21. Upon information and belief, HMRI has agreed under the contract, "to calculate and make a
Rebate Payment to each State Medicaid Agency for [HMRI's] Covered Outpatient Drugs [including
Cardizem CD] paid for by the State Medicaid Agency during a quarter." Appendix A, paragraph 11(a).
Andrx and other manufacturers of generic versions of Cardizem CD have entered similar contracts.
Under these contracts, each state directly invoices the manufacturer based upon the number o f units
paid for by the state in each calendar quarter.
22. The total cost to a State Medicaid agency for the utilization of Cardizem CD or its generic
equivalents is a function of a reimbursement amount paid by the State to pharmacies where the drug was
dispensed minus the contractually agreed rebate payment, which is invoiced by the State Medicaid
Agency directly to the manufacturer. To the extent that Defendants' illegal activities have increased this
total cost, State Medicaid agencies are injured in their business or properly as set forth in 15 U.S.C. §
15.
23. The entry of a generic drug into the market can significantly lower the costs incurred by
consumers o f the brand-name drug. The first generic competitor usually prices its product
approximately 20% lower than the equivalent brand-name drug, while subsequent generic entrants can
cause the price of the initial generic offering to fall as much as 80%. The manufacturer of the brandname drug will typically suffer a substantial decline in its market share immediately after generic
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alternatives are made available to purchasers. Third party payers, such as government prescription drug
assistance programs, also often charge a lower consumer co-payment on purchases of generic drugs
than they do for the drugs' brand-name equivalents.
24. Before a drug may be marketed in the United States, the manufacturer must obtain FDA
approval. To streamline the approval process, and thereby encourage the development of cheaper,
generic drugs, Congress passed the Drug Price Competition and Patent Term Restoration Act o f 1984,
98 Stat. 1585,21 U.S.C. § 355 (the "Hatch-Waxman Act"). Under the Hatch-Waxman Act, a
prospective generic entrant may gain FDA approval by filing an Abbreviated New Drug Application
("ANDA") with the FDA. The ANDA filer must certify that, as o f market entry, the generic drug will
not infringe any patent for an existing drug listed in Approved Drugs with Therapeutic Equivalence

Evaluations , commonly known as the "Orange Book," a compendium of such patents maintained by
the FDA. 21 U.S.C. §355(j)(2)(A)(vii). The ANDA filer may certify that patent information on the
brand-name drug has not been filed, or that such patent has expired, or that the generic will not be
marketed until the date on which such patent will expire. Alternatively, the ANDA filer may make a
"Paragraph IV Certification," by which the applicant asserts that the brand-name patent is invalid, or not
infringed. 21 U.S.C. §355(j)(2)(A)(vii)(IV). The applicant must provide notice of its Paragraph IV
Certification to the maker of the brand-name drug.
25. To provide an impetus to challenge patents and/or design around them, the Act entitles the
first Paragraph IV certified ANDA filer to a 180-day period of marketing exclusivity (the "Exclusivity
Period"), during which the FDA may not grant final approval to any other generic manufacturers
ANDA regarding the same brand-name drug. The Exclusivity Period does not begin to run until either
the first applicant enters the market with its product, or a court enters a final judgment that the patent(s)
subject to the Paragraph IV Certification are invalid or not infringed.
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26.

The Act also makes the filing of a Paragraph TV Certification an ’’artificial act of

infringement" for purposes of patent law. 34 U.S.C. § 2 7 1(e)(2). If the patent holder commences an
infringement action within 45 days o f receiving the Paragraph IV Certification, FDA approval is
automatically stayed until the earlier of (i) the expiration of the relevant patent, (ii) 30 months from the
date of receipt of the Paragraph IV certification, or (iii) a final judicial determination of n o n infringement
or invalidity of the patent. If the 45-day period elapses without an infringement action, final FDA
approval is not contingent on, and will not be delayed by, any subsequently filed patent infringement
action.

B.

HMPT's Acquisition and M aintcnanre o f its Rvnlnsivp. Hold on rard izem CD

27. Cardizem CD is prescribed for the treatment of chronic chest pains and high blood
pressure, and for the prevention of heart attacks. Once prescribed, Cardizem CD is generally taken by
a patient for years.
28. The active ingredient in Cardizem CD is diltiazem hydrochloride ("diltiazem"). The United
States patent on diltiazem expired in November 1992. However, prior to the expiration of the patent
on diltiazem, Cardenn made a patent application claiming the Cardizem CD dissolution profile, which is
the amount of diltiazem released into the blood over a specific period of time. The application claimed
that 0-45% of the total diltiazem in Cardizem CD was released within 18 hours of ingestion, and not less
than 45% was released over a 24 hour period, as measured in a hydrochloric acid test (the "dissolution
profile"). On November 28,1995, the U.S. Patent and Trademark Office issued United States Patent
No. 5,470,584 ("the 584 patent") to Carderm, which licensed it to HMRI. However, the 584 patent
did not in any way extend the patent on the active ingredient, diltiazem, which came "off patent" in 1992
and is in the public domain. Accordingly, since the patent expired diltiazem has been in the public
domain.
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29. Diltiazem-based drugs have been available for treatment of hypertension as early as 1982, .
but the immediate release formulations of the first diltiazem drugs required that patients take three or
four doses per day. As a result, the incidence of non-compliance was high, and users often suffered
from side effects caused by undesirable fluctuations of diltiazem in the blood. Cardizem CD, however,
uses a delay-release formulation, and therefore need be taken only once per day.
30. Cardizem CD's single administration of diltiazem over the course of a day is based on a
sustained release delivery and absorption method claimed in United States patent no. 5,002,776 (the
"776 patent") and United States patent no. 4,894,240 (the "240 patent") (collectively termed the
"controlled absorption formulation patents"). Marion Merrell Dow Corporation ("MMD") and Carderm
were the licensees of the controlled absorption formulation patents.
31. When it was introduced in 1992, Cardizem CD immediately captured a substantial share of
the market. Through 1999, Cardizem CD dominated the once-a-day diltiazem prescription market,
with sales in the United States o f over $700 million in each of 1996 and 1997, and a market share of
almost 80%. During this period, Cardizem CD was the largest revenue producer for HMRI. As a
result, there was intense pressure on HMRTs management to delay market entry by generic competitors
of Cardizem CD until HMRI produced another drug which generated comparable profits.
32. Cardizem CD was first developed and manufactured by Marion Merrell Dow Corporation
("MMD"). HMRI initially obtained the rights to another once-daily diltiazem-based drug known as
Tiazac, via a Rights and Supply Agreement with Biovail.
33. MMD brought an action against HMRI and Biovail, alleging that Tiazac infringed its patent
for Cardizem CD. At first, HMRI contested the suit. But in June 1995, HMRI purchased MMD from
its parent, Dow Chemical Corporation, thereby acquiring the right to market Cardizem CD. It then
terminated the joint venture with Biovail.
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34. Biovail responded by suing HMRI and Carderm for breach of contract and antitrust
violations. The parties eventually settled the suit and, as part of the settlement, HMRI entered into a
broad covenant not to sue Biovail for actions related to diltiazem-based drugs.
35. The FTC launched an investigation into HMRI's purchase of MMD, which was ultimately
settled by consent order. To rectify the anticompetitive effects of the merger, the order specifically
directed HMRI to provide Biovail with a right of reference for the toxicology data that MMD had
submitted to the FDA in support of its initial New Dmg Application (,rNDA") for Cardizem. Toxicology
data demonstrates a drug's safety and efficacy, and is normally quite time consuming and expensive to
generate. By compelling HMRI to authorize use of its toxicology data as support for any NDA filed by
Biovail for a diltiazem-based product, the FTC effectively allowed Biovail to market a generic version of
Cardizem CD by filing an NDA, rather than an ANDA. Normally, FDA approval of an ANDA is
much faster than of an NDA, but with the right of reference, Biovail's NDA could have been approved
as quickly as an ANDA. Further, use o f an NDA would mean that Biovail's generic dmg application
would not be subject to the Hatch-Waxman ANDA regulations, including the "artificial act of
infringement" claim based on notice o f Paragraph IV certification, the statutory 30 month stay or the
Exclusivity Period rules.
36. In accordance with the consent order, HMRI sent a letter to the FDA on December 18,
1995, advising the agency that Biovail was entitled to reference toxicology data from its Cardizem
NDA, and any supplemental NDAs "related to that product." The FDA subsequently confirmed to
Biovail that the right of reference granted by HMRI was broad enough to cover "all future NDA
submissions involving diltiazem-based dmg products that Biovail might file."
37. HMRI did not, however, abide by its promise to die FTC, or the representations set forth in
its letter to the FDA. Instead, on July 11,1996, HMRI informed the FDA by letter that the right of
reference granted to Biovail by HMRI extended only to Tiazac, and that Biovail could not use the right
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of reference for other diltiazem-based products, including Cardizem CD. Neither Biovail nor the FTC
were informed by HMRI that it had chosen to reinterpret its obligations under the consent order and
retreat from its earlier position.
3 8. Biovail did not learn of HMRI's revised stance until informed of it by the FDA by letter
dated November 8, 1996. At the time, Biovail had been planning to file both an ANDA and an NDA
for its version of Cardizem CD. Once HMRI reneged on the commitment it had given the FTC, Biovail
could not seek approval via an NDA without compiling its own toxicology data, which would have
required the expenditure of substantial funds and entailed significant delay.
39. In June 1997, Biovail filed an ANDA for a generic version of Cardizem CD. (The first filer,
Andrx, had filed its ANDA for a generic equivalent of Cardizem CD on September 22, 1995, over one
and one half years earlier.) On August 1,1997, just prior to the end o f the forty-five day period during
which HMRI could delay the generic product's entry by filing suit, HMRI contacted Biovail and initiated
a series of meetings in which HMRI sought to forestall Biovail's sale o f a generic competitor to
Cardizem CD.
40. During these meetings, HMRI offered to pay Biovail a substantial sum of money in exchange
for Biovail's agreement to delay the marketing of its generic competitor to Cardizem CD. In addition,
HMRI promised that it would provide Biovail with a lucrative license to "develop" and sell one of its
other drugs, Probucol. On information and belief, it was intended that this "license" agreement to
develop Probucol would contain no development milestones or targets and would have been a nonrefundable payment by HMRI to Biovail, even if Biovail did nothing to develop Probucol. HMRI also
insisted, as part of their agreement, that Biovail not contact Andrx, the first filer and holder o f the rights
to the Exclusivity Period for a generic Cardizem CD. HMRI refused, however, to grant Biovail the right
o f reference which would have allowed the FDA to grant final approval of Biovail's generic alternative
to Cardizem CD by means of an NDA, and the parties failed to reach agreement.
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41. Because HMRI had previously entered into a covenant not to sue Biovail, it did not bring an
infringement action against Biovail. Nonetheless, because Biovail's AND A was subordinate to Andrx's
rights as the first filer of an ANDA, the entry of Biovail's generic alternative to Caidizem CD was
delayed by the terms of the market division agreement entered into by HMRI and Andrx, the details of
which are set forth below.

C.

The Competitive Threat hy Andrx

42. In August 1995, prior to filing its ANDA and Paragraph IV Certification for a generic
version o f Cardizem CD, Andrx gave samples of its product to HMRI so that HMRI could test Andrx's
version and confirm that it did not infringe the patents claiming Cardizem CD. Andrx shared its samples
with HMRI with the hope of avoiding infringement litigation. In addition, Andrx filed a patent
application with the United States Patent & Trademark Office (the "US PTO") on March 24,1995,
claiming its diltiazem controlled release formulation. On October 22, 1996, the US PTO issued United
States Patent No. 5,567,441 to Andrx.
43. On September 22,1995, Andrx became the first manufacturer to file a Paragraph IV
Certified ANDA for a generic alternative to Cardizem CD with the FDA.
44. After filing its ANDA with the FDA, Andrx notified HMRI of its Paragraph TV Certification,
which stated that the Andrx product did not infringe any unexpired patents fisted in the Orange Book
concerning Cardizem CD.
45. Two months after Andrx filed its ANDA, on November 28, 1995, the US PTO issued
United States Patent No. 5,470,584 (the "584 patent") to HMRI's subsidiary, Carderm was granted the
584 patent on the 0-45% over 18 hours dissolution profile for Cardizem CD. The 584 patent claimed a
dissolution rate from 0-45% of total diltiazem released after 18 hours and not less than 45% o f total
diltiazem released after 24 hours. The 584 patent was immediately listed by HMRI in the Orange
Book as covering Cardizem CD.
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46. On information and belief, the 584 patent was prosecuted and listed solely to give HMRI a
basis for initialing sham litigation to delay and exclude Andrx and other generic manufacturers from
competing with Cardizem CD. Oh information and belief, the Andrx product did not infringe on the 584
patent.
47. On January 31, 1996, HMRI and Carderm filed a patent infringement suit against Andrx in
the United States District Court for the Southern District of Florida, claiming that Andrx's generic
product would infringe the 584 patent. The filing of the suit triggered the 30-month Hatch-Waxman Act
waiting period, during which the FDA could not finally approve Andrx's product for marketing, unless
the patent suit was fully resolved.
48. On April 4,1996, Andrx amended its AND A to increase the dissolution rate of its generic
product to 55% over 18 hours ("Andrx's Amended AND A"), thereby making its product even more
distinct from Cardizem CD. The increased dissolution rate specified by Andrx was within the
dissolution range that Carderm had specifically canceled from its application for the '584 patent Andrx
gave notice of this change to HMRI, which nonetheless persisted with its infringement litigation.
49. On information and belief, the change in the dissolution profile precluded HMRI from having
a realistic expectation of success in the infringement suit. On information and belief, HMRI maintained
its infringement action against Andrx with the intent of delaying the market entry of a generic competitor.
50. During the pendency of Andrx's Amended ANDA, a third generic manufacturer, Purepac,
filed its ANDA in January 1997. HMRI responded by commencing a patent infringement action against
Purepac, which stayed FDA approval o f Purepac's product until July 1999.
51. During the first half of 1997, Andrx readied Cartia XT for sale. Andrx ordered machines,
produced initial batches of product, prepared marketing materials and hired new employees.
Simultaneously, Andrx officials began to discuss with their counterparts at HMRI the possibility of
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entering into an agreement under which Andrx would postpone the marketing o f its generic equivalent to
Cardizem CD.
52. On September 17,1997, the FDA gave preliminary approval to Andrx's Amended ANDA
for its generic version o f Cardizem CD. Such approval meant that on July 8, 1998 (or sooner, if the
patent case was resolved), Andrx would be free to enter the market. Upon information and belief,
Andrx fully intended to market its product as soon as it was legally permitted to do so, unless it could
secure an agreement with HMRI, by which HMRI would compensate it for refraining from selling its
generic alternative to Cardizem CD. But for the agreement with HMRI, Andrx would have begun
marketing its generic version of Cardizem CD on or shortly after July 8, 1998.

D.

HMRT and AnHrv's Illegal Agreement

53. On September 24, 1997, one week after Andrx received preliminary FDA approval for its
amended ANDA, HMRI and Andrx entered into the HMRI/Andrx Stipulation and Agreement (the
"Agreement" or "the HMRI-Andrx Agreement").
54. The Agreement delayed the appearance of a generic competitor to Cardizem CD,
guaranteed that HMRI would maintain its 100% share of the market for Cardizem CD and its AB-rated
bioequivalents, and effectively insured HMRI's continued dominance over the once-a-day diltiazem
prescription drug market. Under the Agreement, Andrx promised not to sell a generic version of
Cardizem CD, regardless o f whether its product infringed HMRI's patent, unless Andrx obtained a
license from HMRI under terms specified in the Agreement, or HMRI provided Andrx with notice that
it intended to license Cardizem CD to a third party. The Agreement was to last until the entry of a final
judgment in the patent litigation.
55. In addition to withholding its product from the market, Andrx agreed to diligently prosecute
its ANDA, so as to preserve its right to the Exclusivity Period, and not to relinquish any right to which it
was entitled thereunder during the pendency of the Agreement, including selling or transferring its right to
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the Exclusivity Period. Since the Exclusivity Period would not begin to run until Andrx actually entered,
the market or the patent lawsuit was resolved, the Agreement effectively blocked any other
manufacturer from selling a generic version of Cardizem CD. Indeed, the sole benefit HMRI received
from these contractual terms was to shield Cardizem CD from competition from other potential generic
entrants. On infonnation and belief, in or about July 1998, there was at least one generic manufacturer
who was prepared to purchase Andrx's rights as first filer and enter the market with a generic version of
Cardizem CD, and who made an offer to Andrx to that effect.
56. HMRI paid heavily to maintain its monopoly in this profitable market. Pursuant to the
Agreement, HMRI was obligated to start making quarterly "interim payments" to Andrx of $10 million
each as o f July 9, 1998, the day after Andrx otherwise could have entered the market. The payments
would not terminate until the patent case reached final resolution, including all appeals. If Andrx won
the case, HMRI had to pay Andrx an additional $60 million per year from July 9,1998, until the date
that the final judgment became effective, bringing Andrx's total payments to $ 100 million per year of
delayed entry. If Andrx lost the patent suit, the Agreement would still provide Andrx with a licensing
option.
57. The Agreement specifically did not settle the patent litigation, and was not presented to the
court handling that case. Indeed, the Agreement required the parties to keep its terms a secret, and
stated explicitly that it was never to be filed in any court proceeding.
58. In September 1998, Andrx filed a supplement to its ANDA, specifying a 65% dissolution
profile for its product. This amendment fiirther undermined the already remote possibility that HMRI's
infringement action against Andrx would be successful.
59. On June 9, 1999, following the commencement of private antitrust litigation based on the
Agreement, HMRI and Andrx announced that they had agreed to settle their patent suit. They claimed
that the settlement had been made possible by Andrx's ANDA amendments, and its concomitant
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reformulation of its generic version of Cardizem CD. At the time of settlement, HMRI paid Andrx an
additional $50,700,000, bringing its total payments to Andrx to $89,830,000.
60. On June 23, 1999, Andrx began marketing Cartia XT, its generic alternative to Cardizem
CD. Cartia XT sold for approximately 10% less than Cardizem CD. Within six months, HMRI's share
of the market for Cardizem CD and its AB-rated bioequivalents dropped to approximately 50%.
61. Because of HMRI's Agreement with Andrx, and the resulting delay in Andrx's entry into the
market, Andrx's Exclusivity Period did not finally expire until December 1999.
62. In July 1999, generic drug manufacturer Purepac received final FDA approval for its
generic version of Cardizem It setded its patent litigation with HMRI by entering into a licensing
agreement, which permitted Purepac to sell its generic alternative. However, Purepac could not come
to market until December 1999, when Andrx's Exclusivity Period expired.
63. In October 1999, the FDA approved Biovail's ANDA for its generic version of Cardizem
CD. Biovail also could not sell its product at that time, because of the bottleneck created by Andrx's
exclusive right to market a generic version of Cardizem CD.
64. Once all three generic competitors to Cardizem CD reached the market, HMRI's market
share plummeted to 30%. The prices of the generic drugs also fell, until they were available at 60% less
than the brand-name price.
65. On June 6,2000, Federal District Court Judge Nancy Edmunds issued a Memorandum
Opinion and Order Granting Plaintiifs' Motion for Partial Summary Judgment, which mled that
Defendants' September 24,1997, Agreement constituted a per se violation of Section One of the
Sherman Act. In Re: Cardizem CD Antitrust Litig., 105 F. Supp. 2d 682, (E.D. Mich. 2000).
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V.

CONSUMER REPRESENTATION

66. The Plaintiff States, through their Attorneys General, bring this action, individually and as
authorized by law in a statutory, equitable and/or common law capacity, as parens patriae or its
functional equivalent on behalf of all natural persons residing in the Plaintiff States and/or, in those
Plaintiff States (Alaska, Alabama, Arkansas, California, Connecticut, Georgia, Indiana, Iowa, Kansas,
Kentucky, Maine, Massachusetts, Montana, Nebraska, Nevada, North Carolina, Oklahoma, South
Carolina, Utah, Wisconsin, Wyoming) where such class actions are asserted by Attorneys General,
pursuant to Rules 23 (a) and 23 (b) of the Federal Rules of Civil Procedure, on behalf of all natural
persons residing in the Plaintiff States who purchased Cardizem CD and AB3 rated bioequivalents from
January 1, 1998, through a date found to be appropriate by the Court.
67. There are thousands of consumers who purchased Cardizem CD and AB3 rated
bioequivalents from pharmacies and drug stores across the country at supra-competitive levels due to
the conduct o f Defendants.
68. Joinder of all consumer purchasers of Cardizem CD and AB3 rated bioequivalents would
be impracticable.
69. There are questions of law and fact common to natural person consumers of Cardizem CD
and AB3 rated bioequivalents, including:
a)

Whether the exclusive agreement between Defendants whereby
Defendant Andix would keep its generic version of Cardizem CD
out of the market place in exchange for payments totaling $89
million dollars unreasonably restrained trade under Section 1 of the
Sherman Act, 15 U.S.C. § 1;
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b)

Whether the exclusive agreements between Defendants whereby
Defendant Andrx would keep its generic version of Cardizem CD
out o f the market place in exchange for payments totaling $89
million dollars created monopoly power under Section 2 of the
Sherman Act, 15 U.S.C. § 2;

c)

Whether Defendants Hoechst A.G., Aventis, HMRI, Carderm, and
Andrx conspired to fix, raise or stabilize the price of Cardizem CD
under Section 1 of the Sherman Act, 15 U.S.C. §1;

d)

The period and extent of Defendants' illegal conspiracy alleged
herein; and

e)

The suitable measure of damages suffered by natural person
consumers residing in the Plaintiff States resulting from Defendants'
illegal conduct.

70. The prosecution o f separate actions by individual consumers would create a risk of
inconsistent or varying adjudications, potentially establishing incompatible standards of conduct for the
Defendants.
71. Common questions of law and fact predominate over any questions affecting only individual
consumers, including legal and factual issues relating to liability and damages.
72. Parens patriae and class representation by the State Attorneys General is superior to other
available methods for the appropriate and efficient adjudication o f this controversy, the State Attorneys
General are the best qualified representatives and will fairly and adequately protect the interests of
consumers, whether pursuant to parens patriae or class representation, and this action will eliminate die
possibility o f repetitious litigation, while also providing a remedy for claims too small to make practicable
the expense of individual, complex litigation.
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VI.

RELEVANT MARKET

73. A relevant product market for assessing Defendants' anticompetitive acts is the market for
Cardizem CD and its FDA-approved, AB-rated, bioequivalents. Under FDA regulations, once a
physician prescribes Cardizem CD, the patient may only purchase that drug or its AB-rated
bioequivalent. Other once-a-day diltiazem medications cannot be substituted by the pharmacist or
consumer without a new prescription. Thus, from the perspective of consumers, the prescribing
practices of their physicians limit consumers' purchasing options to the prescribed brand-name drug, and
its approved AB-rated generic alternatives, if any.
74. Until the entry of Cartia XT, HMRI had an absolute monopoly in this market.
75. Alternatively, a relevant product market for assessing Defendants' anticompetitive acts is the
market for once-a-day extended release diltiazem prescription drugs. Neither other forms of diltiazem,
nor other medications for treatment of hypertension and prevention of heart attacks, effectively compete
with once-a-day diltiazem.
76. Until the entry of Cartia XT, HMRI had an effective monopoly in this market.
77. The relevant geographic market is the United States.

VII.

INTERSTATE COMMERCE

78. At all times relevant to this Complaint, HMRI and its successor Aventis have participated in
the market for Cardizem CD and its FDA-approved, AB-rated, bioequivalents, or alternatively, the
market for once-a-day diltiazem prescription drugs in the United States. At all times relevant to this
Complaint, Defendant Andrx either prepared to, or did in fact, participate in this market.
79. The activities of the Defendants, including manufacturing, marketing, distributing and selling
pharmaceutical products, were in the regular, continuous and substantial flow of interstate commerce
and have had and continue to have a substantial effect on interstate commerce.
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V ili.

EFFECTS OF DEFENDANTS'ILLEGAL CONDUCT

80. The Defendants' acts and practices had the purpose or effect, or the tendency or capacity,
to restrain competition unreasonably and to injure competition within each State and throughout the
United States, by:
a)

Depriving direct and indirect purchasers of Cardizem CD o f less
expensive, comparable, generic alternatives;

b)

Maintaining the monopoly price of Cardizem CD for pharmacies,
hospitals, insurers, managed care organizations, wholesalers,
government agencies, consumers, and others who purchased
Cardizem CD, but who would otherwise have purchased a generic
alternative, if one were available;

c)

Delaying the establishment of MAC prices and restricting the
negotiation of larger discounts or rebates for both Cardizem CD
and its generic alternatives;

d)

Depriving consumers of the benefits of competition among generic
pharmaceutical manufacturers and delaying the entry of new
competitors;

e)

Depriving consumers of access to needed pharmaceuticals, and
thereby injuring their health; and

f)

Injuring the States' economies, by engaging in collusive behavior
that distorted the process of free and open competition.

81. Many of the injured purchasers, including bureaus, agencies and departments o f state
governments, purchase generic drugs, when they are available, as a matter of policy or practice.
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Defendants' anticompetitive acts deprived these purchasers of the ability to implement such policies or ,
practices, and to select a cheaper alternative to Cardizem CD or to obtain Cardizem CD less
expensively.
82.

The Defendants' acts and practices had the purpose or effect, or the tendency or capacity,

and did unjustly enrich the Defendants.

IX.

INJURY

83. As a direct and proximate result of the unlawful conduct alleged above, from July 1998,
through June 1999, the States and consumers residing therein were not able to purchase a generic
version o f Cardizem CD, and they have consequently been injured in their business and property in that,

inter alia , they have paid more for once-a-day diltiazem prescription drugs than they would have paid
but for HMRI's and Andrx's anti-competitive practices, because they were unable to purchase generic
alternatives to Cardizem CD that would have been available but for Defendants' acts.
84. As a direct and proximate result of the unlawful conduct alleged above, consumers in the
Plaintiff States paid, and continue to pay, higher prices for Cardizem CD and/or the generic versions of
Cardizem CD now available, because of the delay caused by HMRI's and Andix's anti-competitive
conduct, and its effect on generic price decreases, larger discounts and larger rebates that inevitably
appeal* upon the entry of multiple generic competitors.
85. As a direct and proximate result of the unlawful conduct alleged above, the States have
sustained injury, and are threatened with further injury unless the Defendants are enjoined from engaging
in similar unlawful conduct in the future. The States do not have an adequate remedy at law for such
conduct.
86. As a direct and proximate result o f the unlawful conduct alleged above, HMRI has unjustly
profited by maintaining a higher share o f the market for once-a-day diltiazem than it would have enjoyed
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absent its anti-competitive acts, and by maintaining a 100% share of the market for Cardizem CD and
its AB-rated bioequivalents. Andrx has unjustly profited by receiving payments pursuant to an illegal
and unreasonable agreement in restraint of trade, and by delaying competition from other generic
entrants.

X.

FIRST CLAIM FOR RELIEF
VIOLATION OF SECTION 1
OF THE SHERMAN ACT

87. The States repeat and reallege Paragraphs 1 through 86.
88. From September 1997, until June 1999, Defendants engaged in a continuing combination,
conspiracy, and arrangement in unreasonable restraint of interstate trade and commerce in violation o f
Section 1 o f the Sherman Act, 15 U.S.C. § 1.
89. The combination, conspiracy, and arrangement consisted o f an agreement between and
among HMRI and Andix to allocate to HMRI the market for Cardizem CD and its AB-rated
bioequivalents, or alternatively, the market for once-a-day extended release diltiazem prescription
drugs, by keeping Cardizem CD free from generic competition from July 1998, through June 1999, and
further delaying the entry o f other generic competitors thereafter. In return for postponing its own entry,
and thereby delaying all generic entry into the market, Andix received nearly $90 million from HMRI.
This combination, conspiracy, arrangement and agreement was in violation of Section 1 of the Sherman
Act.
90. By delaying entry of generic versions o f Cardizem CD, HMRI denied consumers access to
less expensive, medically equivalent alternatives to its product, thus causing consumers, government
agencies and others who purchase or reimburse others for the purchase of Cardizem CD to pay more
than they would have under natural conditions of competition in the absence of such illegal restraints of
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trade. The restraint also impeded the establishment of larger discounts, rebates or other price caps
which would have resulted in lower prices for Cardizem CD and/or its generic alternatives.

XI. SECOND CLAIM FOR RELIEF
MONOPOLIZATION OF THE MARKET FOR CARDIZEM CD
AND ITS BIOEQUIVALENTS, OR ALTERNATIVELY,
THE MARKET FOR ONCE-A-DAY DILTIAZEM PRESCRIPTION DRUGS,
IN VIOLATION OF SECTION 2 OF THE SHERMAN ACT.
91. The States repeat and reallege Paragraphs 1 through 90.
92. HMRI and Hoechst A.G. have engaged in exclusionary, anti-competitive conduct designed
to prevent competition on the merits between HMRI and its generic competitors, including but not
limited to: a) the formation of an illegal agreement with Defendant Andrx; and b) engaging in various
efforts intended to prevent or induce Biovail to refrain from marketing a generic alternative to Cardizem
CD. These acts were intended to and did allow HMRI and Hoechst A.G. to maintain their monopoly
power in the market for Cardizem CD and its AB-rated bioequivalents, or alternatively, in the market
for once-a-day diltiazem prescription drugs, in violation of Section 2 of the Sherman Act, 15 U.S.C. §

2.
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XII.
THIRD CLAIM FOR RELIEF
ATTEMPTED MONOPOLIZATION OF THE MARKET FOR
CARDIZEM CD AND ITS BIOEQUIVALENTS, OR ALTERNATIVELY,
THE MARKET FOR ONCE-A-DAY DILTIAZEM PRESCRIPTION DRUGS IN
VIOLATION OF SECTION 2 OF THE SHERMAN ACT
93. The States repeat and reallege Paragraphs 1 through 92.
94. HMRI and Hoechst A.G. engaged in a course of exclusionary conduct in order to obtain or
maintain their monopoly over the markets for once-a-day diltiazem and for Cardizem CD and its ABrated bioequivalents including: a) the formation of an illegal agreement with Defendant Andix; and b)
engaging in various efforts intended to prevent or induce Biovail to retrain from marketing a generic
alternative to Cardizem CD.
95. At all relevant times, HMRI and Hoechst A.G. acted with a specific intent to monopolize,
and to destroy competition in the market for Cardizem CD and its AB-iated bioequivalents, or
alternatively in the market for once-a-day diltiazem prescription drugs, in violation of Section 2 of the
Sherman Act, 15 U.S.C. § 2.
96. At the time HMRI and Hoechst A.G. engaged in these acts, they had a dangerous
probability o f succeeding in obtaining or maintaining a monopoly on the sale of Cardizem CD and its
AB-rated bioequivalents and alternatively on the sale of once-a-day diltiazem prescription drugs.

XIII.

SUPPLEMENTAL STATE LAW CLAIMS

97. Plaintiff State o f New York repeats and realleges each and every allegation contained in
Paragraphs 1 through 96.
98. Defendants' acts violate N.Y. Gen. Bus. Law §§ 340-347, and constitute fraudulent or
illegal acts under N.Y. Exec. Law § 63(12) and deceptive acts under N. Y. Gen. Bus. Law § 349.
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99. Plaintiff State of Michigan repeats and realleges each and every allegation contained in
Paragraphs 1 through 96.
100.

Defendants' acts violate the Michigan Antitrust Reform Act, Mich. Comp. Laws §

445.771 et seq . Specifically, but without limitation, Michigan is entitled to redress pursuant to Mich.
Comp. Laws §§ 445.777 and 445.778.
101.

Plaintiff State of Alabama repeats and realleges each and eveiy allegation contained in

Paragraphs 1 through 96.
102.

The aforementioned practices by Defendants were in violation o f the Code o f Alabama,

Ala. Code § 8-10-1 et seq. (1975). The State o f Alabama represents consumers’ claims pursuant to
the Attorney General's parens patriae authority.
103.

Plaintiff State of Alaska repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
104.

Defendants' acts violate Alaska's Restraint of Trade Act, Alaska Stat.§ 45.50.562 et

seq., and Alaska's Unfair Trade Practices and Consumer Protection Act, Alaska Stat. § 45.50.461 et
seq .
105.

Plaintiff State of Arizona repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
106.

Defendants' acts violate the Arizona Uniform State Antitrust Act, Ariz. Rev, Stat. Ann.

§ 44-1401 et seq. Specifically, but without limitation, Defendants' practices are in violation of Ariz.
Rev. Stat. Ann. §§ 44-1402 and 44-1403.
107.

Plaintiff State of Arkansas repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
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108.

Defendants' acts violate the Arkansas Deceptive Trade Practices Act, Ark. Code Ann.

§ 4-88-101 et seq, Specifically, but without limitation, Defendants' practices are in violation of Ark.
Code Ann. § 4-88-107.
109.

Plaintiff State o f California repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
110.

Defendants' acts violate California's Cartwright Act, Cal. Bus. & Prof. Code § 16720

et seq, and California's Unfair Competition Act, Cal. Bus. & Prof. Code §17200 et seq.
111.

Plaintiff State o f Colorado repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
112.

Defendants' act violate the Colorado Antitrust Act, Colo. Rev. Stat § 6-4-101 et seq .

113.

Plaintiff State of Connecticut repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
114.

Defendants' acts violate the Connecticut Antitrust Act, Conn. Gen. Stat. § 35-24 et

seq,, and the Connecticut Unfair Trade Practices Act, Conn. Gen. Stat. § 42-110a et seq.
115.

Plaintiff State Delaware repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
116.

The aforementioned practices by Defendants were in violation o f the Delaware Antitrust

Act, Del. Code Ann. tit. 6, chapter 21, and Delaware's Uniform Deceptive Trade Practices Act, Del.
Code Ann, tit. 6, Subchapter 111 § 2532. The State of Delaware represents consumers' claims
pursuant to the Attorney General's parens patriae authority.
117.

Plaintiff District of Columbia repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
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118.

Defendants' acts were in violation of the District o f Columbia Antitrust Act, specifically

D.C. Official Code §§ 28-4502 and 28-4503 (2001). The laws of the District of Columbia are
included in the term "state law" as used in this Complaint.
119.

Plaintiff State of Florida repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
120.

Defendants' acts violate the Florida Antitrust Act o f 1980, Fla. Stat. § 542.15, et seq.,

and the Florida Deceptive and Unfair Trade Practices Act, Fla. Stat. § 501.201, et seq.
121.

Plaintiff State of Georgia repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
122.

Defendants' acts violate the O.C.G.A. § 13-8-2 and Ga. Const. Art. Ill, § VI, f 5

123.

Plaintiff State of Hawaii repeats and realleges each and every allegation contained in

(1983).

Paragraphs 1 through 96.
124.

Defendants' acts violate Hawaii Revised Statutes Chapter 480, Monopolies; Restraint

o f Trade. Specifically, but without limitation, Defendants' acts violate Haw. Rev. Stat. § 480-2, § 4804, and § 480-9.
125.

Plaintiff State of Idaho repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
126.

Defendants' acts violate the Idaho Competition Act, Idaho Code §48-101 et seq.

(2000 Supp.) Specifically, but without limitation, Defendants' acts violate Idaho Code §§ 48-104 and
48-105 (2000 Supp.).
127.

Plaintiff State o f Illinois repeats and realleges each and every allegation contained in

paragraphs 1 -96.
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128.

Defendants' acts violate, and Plaintiff State of Illinois is entitled to relief under the Illinois

Antitrust Act, 111. Rev. Stat. ch. 740 para. 10/1 et seq., including without limitation 111. Rev. Stat. ch. 740
para. 10/3 (1) - (3).
129.

Plaintiff State of Indiana repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
130.

Defendants' acts violate the Ind. Code §§ 24-1-1-1, 24-1-2-1, and 24-1-3-1.

131.

Defendants' acts violate Ind. Code § 24-5-0.5-3: Acts constituting deceptive practices

Sec. 3. (a) The following acts or representations as to the subject matter of a consumer transaction,
made either orally or in writing by a supplier, are deceptive acts: (1) That such subject of a consumer
transaction has sponsorship, approval, performance, characteristics, accessories, uses, or benefits it
does not have which the supplier knows or should reasonably know it does not have. This applies to the
transactions generally and allows Indiana to proceed in its parens patriae authority pursuant to Ind.
Code 24-5-0.5-4(c)(2).
132.

Plaintiff State of Iowa repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
133.

Defendants' acts violate the Iowa Competition Law, Iowa Code §§ 553 et seq., and

the Consumer Fraud Act, Iowa Code § 714.16.
134.

Plaintiff State of Kansas repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
135.

Defendants' acts violate the Kansas Restraint o f Trade Act, Kan. Stat. Ann. §50-101

et seq ., and its predecessor, and constitute unconscionable acts and practices in violation the Kansas
Consumer Protection Act, Kan. Stat. Ann. § 50-623 et seq.
13 6.

Plaintiff State of Kentucky repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
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137.

The aforementioned practices by the Defendants were in violation of Kentucky Revised

Statutes, Ky. Rev. Stat § 367.175, and the Kentucky Consumer Protection Act, Ky. Rev. Stat. §
367.110 et seq.
138.

Pursuant to Ky. Rev. Stat. § 367.110 et seq ., the Commonwealth o f Kentucky brings

this action for damages sustained by the Commonwealth of Kentucky and its natural person citizens,
together with costs and attorneys fees, civil penalties and all available equitable relief, including injunctive
relief and restitution and disgorgement. The Commonwealth of Kentucky represents consumers' claims
pursuant to the Attorney General's parens patriae authority and authority under Rule 23 of the Federal
Rules of Civil Procedure.
139.

Plaintiff State of Louisiana repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
140.

The aforementioned practices of Defendants were in violation of the Louisiana

Monopolies Act, La. Rev. Stat. Ann. § 51:121, et seq. and the Louisiana Unfair Trade and Consumer
Protection Act, La. Rev. Stat. Ann. § 51:1401, et seq. The State of Louisiana is entitled to redress
pursuant to La. Rev. Stat. Ann. §§ 51:136-139, 5L1404B, and 51:1407-1409.
141.

Pursuant to La. Rev. Stat. Ann. §§ 137 and 138, and La. Rev. Stat. Ann. §§

51:1404B, 1408-1409 and 1414, an acting under the Attorney General's specific authority to bring all
Louisiana Monopolies Act actions and any unfair trade action, the State of Louisiana brings this action
to recover three times the damages suffered by Louisiana consumers and/or state agencies as a result to
Defendants' illegal, anticompetitive conduct.
142.

The State of Louisiana also seeks statutory penalties, costs, disbursements and

attorneys fees from Defendants, as well as all available injunctive relief pursuant to La. Rev. Stat. Ann.
§§ 122-123,129, 130, 138 and 139, La. Rev. Stat. Ann. §§ 5L1404B, 1408, 1409 and 1414. The
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State o f Louisiana represents consumers' claims pursuant to the Attorney General's parens patriae
authority and authority under Rule 23 of the Federal Rules of Civil Procedure.
143.

Plaintiff State of Maine repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
144.

Defendants' acts violate the Maine "mini-Sherman Act," Me. Rev. Stat. Ann. tit. 10 §

1101 et seq., and the Maine Unfair Trade Practices Act, Me. Rev. Stat. Ann. tit. 5 § 205-A et seq.
145.

Plaintiff State of Maryland repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
146.

The aforementioned practices by Defendants were, and are in violation of the Maryland

Antitrust Act, Md. Com. Law Code Ann. § 11-201 et seq.
147.

Plaintiff State of Maryland brings this action for three times the amount of damages

sustained by the State and for civil penalties and all available equitable relief on behalf o f the State and
natural person citizens, including injunctive relief, restitution and divestiture or disgorgement, together
with reimbursement o f reasonable attorneys' fees, experts' fees and costs from Defendants pursuant to
Md. Code Ann. Com. Law § 11-209. The State of Maryland represents consumers' claims pursuant to
the Attorney General's equitable authority under Md. Code Arm. Com. Law § 11-209.
148.

Plaintiff Commonwealth of Massachusetts repeats and realleges each and every

allegation contained in Paragraphs 1 through 96.
149.

Defendants' acts were in violation of the Massachusetts Consumer Protection Act, Ma.

Gen. L. C.93A, Sec. 1 et seq. The Commonwealth of Massachusetts represents consumers' claims
under Rule 23 of the Federal Rules of Civil Procedure.
150.

Plaintiff State o f Minnesota repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
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151.

Defendants' acts violate the Minnesota Antitrust Law of 1971, Minn. Stat. §§

325D.49-.66 and Minn. Stat. § 8.31.
152.

Plaintiff State of Mississippi repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
153.

The aforementioned practices by Defendants were in violation of Mississippi Code

Annotated, Miss. Code Ann. §§ 75-21-1 etseq. and 75-24-1 et seq. The State of Mississippi
represents consumers' claims pursuant to the Attorney General's parens patriae authority and authority
under Rule 23 of the Federal Rules of Civil Procedure.
154.

Plaintiff State of Missouri repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
155.

Defendants' acts violate the Missouri Antitrust Law, Mo. Rev. Stat. § 416.011 (2000)

et seq ., sp ecifically, § § 416.031.1, 416.031.2, and 416.031.3. The State of Missouri represents
consumers claims pursuant to the Attorney General's parens patriae authority.
156.

Plaintiff State of Montana repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
157.

The aforementioned practices by Defendants were in violation o f Mont. Code Ann. §

30-14-205. The State of Montana represents consumers' claims pursuant to the Attorney General's

parens patriae authority and authority under Rule 23 of the Federal Rules of Civil Procedure.
158.

Plaintiff State of Nebraska repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
159.

The aforementioned practices by Defendants were in violation of Neb. Rev. Stat. §§

59-801 & 59-831 and §§ 59-1601 & 59-1623 (1998). The State o f Nebraska represents consumers'
claims pursuant to the Attorney General's authority under Rule 23 of the Federal Rules o f Civil
Procedure.
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160.

Defendants' acts violate Nebraska state antitrust statutes: the Junkin Act, Neb. Rev.

Stat. §§ 59-801 et seq. (1998, Cum. Supp. 2002), and the Nebraska Consumer Protection Act, Neb.
Rev. Stat. §§ 59-1601 et seq . (1998, Cum. Supp. 2002).
161.

Plaintiff State of Nevada repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
162.

Defendants' acts violate the Nevada Unfair Trade Practices Act, Nev. Rev. Stat. §

598A.010 etseq. Specifically, but without limitation, Defendants' acts violate Nev. Rev. Stat. §
598A.060.
163.

Plaintiff State of New Hampshire repeats and realleges each and every allegation

contained in Paragraphs 1 through 96.
164.

The aforementioned practices by Defendants were in violation of N.H. Rev. Stat. Ann.

§ 356. The State o f New Hampshire represents consumers' claims pursuant to the Attorney General's

parens patriae authority.
165.

Plaintiff State of New Jersey repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
166.

The aforementioned practices of defendants were in violation of the New Jersey

Antitrust Act, Title 59, Ch. 9, N.J. Stat. Ann. 56:9-1 et seq. The State of New Jersey represents the
claims and interests of New Jersey consumers pursuant to the State Attorney General's parens patriae
authority.
167.

Plaintiff State of New Mexico repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
168.

Defendants' acts violate the New Mexico Antitrust Act, N.M. Stat. Ann. § 57-1-1, et

seq. (1978) and the New Mexico Unfair Practices Act, N.M. Stat. Ann. § 57-12-1 et seq. (1978).
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169.

Plaintiff State of North Carolina repeats and realleges each and every allegation

contained in Paragraphs 1 through 96.
170.

Defendants' acts violate N.C. Gen. Stat. §§ 75-1 et seq.

171.

Plaintiff State of North Dakota repeats and realleges each and every allegation

contained in Paragraphs 1 through 96.
172.

Defendants' acts violate North Dakota's Uniform State Antitrust Act, N.D. Cent. Code

§ 51-OS. 1-01 etseq. (1999).
173.

Plaintiff State of Ohio repeats and realleges each and every allegation contained in

Paragraphs 1 through 96,
174.

Defendants' acts violate Ohio's antitrust law, the Ohio Valentine Act, Ohio Rev. Code

§§1331.01 et seq., Ohio Rev. Code §109.81, and the common law of Ohio.
175.

Pursuant to Ohio Rev. Code §§109.81,1331.03, 1331.08 and 1331.11, the State o f

Ohio brings this action for two times the amount of damages sustained by the State and its natural
person citizens, together with costs and attorney fees, civil penalties, and all other available equitable
relief, including injunctive relief and restitution and disgorgement. The State of Ohio represents
consumers' claims pursuant to the Attorney General's parens patriae authority.
176.

Plaintiff State o f Oklahoma repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
177.

Defendants' acts violate the Oklahoma Antitrust Reform Act, Okla. Stat. tit. 79 § 201

et seq . (1998) and the Oklahoma Consumer Protection Act Okla. Stat. tit. 15 § 751 et seq.
178.

Plaintiff State of Oregon repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
179.

The State of Oregon brings this action for civil penalties and all available equitable relief,

including injunctive relief, restitution and disgorgement, together with reimbursement o f reasonable
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attorneys fees, experts' fees, and costs from Defendants, pursuant to the Oregon Antitrust Law, Or.
Rev. Stat. 646.705 etseq., with specific reference to Or. Rev. Stat. 646.760, 646.770, 646.775, and
the authority under Oregon common law. The State of Oregon represents consumers' claims pursuant
to the Attorney General's parens patriae authority.
180.

Plaintiff State of Pennsylvania repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
181.

The aforementioned practices by Defendants were and are in violation of Pennsylvania

common law doctrines against the unlawful restraint of trade, unjust enrichment and civil conspiracy to
commit an unlawful or tortious act. The Commonwealth of Pennsylvania represents consumers claims
pursuant to the Attorney General's parens patriae authority, 71 Pa. Cons. Stat. Ann. §732-204(c).
182.

Plaintiff Commonwealth of Puerto Rico repeats and realleges each and every allegation

contained in Paragraphs 1 through 96.
183.

Defendants' acts violate the "Act to Prohibit Monopolistic Practices and Protect Fair

and Free Competition in Trade and Commerce," 10 P.R. Laws Ann. § 257-276, and the "Act for a
Class Suit for Consumers o f Goods and Services, 32 P.R. Laws Ann. §3341- §3344. The laws o f the
Commonwealth of Puerto Rico are included in the term 'state law' as used in this complaint.
184.

Plaintiff State of Rhode Island repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
185.

Defendants' acts violate the Rhode Island General Laws Antitrust Act, R.I. Gen. Laws

§ 6-36-1 et seq. Specifically, but without limitation, Defendants' acts violate R.I. Gen. Laws §§ 6-365; 6-36-6.
186.

Plaintiff State of South Carolina repeats and realleges each and every allegation

contained in Paragraphs 1 through 96.
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187.

Defendants' acts violate the South Carolina Unfair Trade Practices Act, S.C. Code

Ann. § 39-5-10, et seq.
188.

Plaintiff State of South Dakota repeats and realleges each and every allegation

contained in Paragraphs 1 through 96.
189.

Defendants' acts violate South Dakota's antitrust laws, S.D. Codified Laws eh, 1-37.

190.

Plaintiff State of Tennessee repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
191.

Defendants' acts violate Tenn. Code Ann. § 47-25-101 et seq. The State of

Tennessee is entitled to damages pursuant to Tenn. Code Ann. § 47-25-106.
192.

The State of Tennessee also brings this action pursuant to Tenn. Code Ann. § 8-6-109

to recover damages pursuant to Tenn. Code Ann. § 47-25-106 suffered by Tennessee governmental
entities as a result of the Defendants' illegal and anticompetitive acts. The State of Tennessee also seeks
penalties, costs, disbursements and attorney fees from Defendants, together with any and all injunctive
relief to which the State of Tennessee may be entitled.
193.

Defendants' acts violate Tenn. Code Ann. § 47-18-101 et seq . (the Tennessee

Consumer Protection Act o f 1977). The State of Tennessee is entitled to recover three (3) times the
damages suffered as a result of Defendants' illegal and anticompetitive actions, together with a civil
penalty o f $ 1,000.00 for each violation o f the Act.
194.

Acting under the authority of the Attorney General and Reporter pursuant to Tenn.

Code Ann. § 47-18-108, the State of Tennessee brings this action under Tenn. Code Ann. § 47-18101 et seq . (The Tennessee Consumer Protection Act) to recover (3) times the damages pursuant to
Tenn. Code Ann. § 47-18-106 suffered by Tennessee consumers as a result of the Defendants’ illegal
and anticompetitive actions together with a civil penalty of $1,000.00 for each violation of the act.
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195.

The State o f Tennessee also brings this action pursuant to Tenn. Code. Ann. §§8-6-

109 and 47-18-101 etseq. (the Tennessee Consumer Protection Act) to recover three (3) times the
damages pursuant to Tenn. Code Ann. § 47-18-106 et seq. suffered by Tennessee governmental
entities as a result of the Defendants' illegal and anticompetitive acts together with a civil penalty of
$1,000.00 for each violation of the Act. The State of Tennessee also seeks penalties, costs,
disbursement and attorneys fees form Defendants, together with any and all injunctive relief to which the
State o f Tennessee may be entitled.
196.

Plaintiff State of Texas repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
197.

Defendants' acts violate § 15.05(a) and (b) of the Texas Free Enterprise and Antitrust

Act o f 1983, Tex. Bus. & Com. Code § 15.01 et seq. ("the Texas Antitrust Act".) The State o f Texas
is entitled to redress pursuant to § 15.20(a) and (b) of the Texas Antitrust Act.
198.

Plaintiff State of Utah repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
199.

Defendants' acts violate the Utah Antitrust Act, Utah Code Ann. §§76-10-911 through

76-10-926 (1999 Replacement, as amended) and the common law of Utah. Specifically, but without
limitation, Defendants' acts violate Utah Code Ann. § 76-10-914(1) and § 76-10-914(2).
200.

Plaintiff State of Vermont repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
201.

Defendants' acts violate the Vermont Consumer Fraud Act, Vt. Stat. Ann. tit. 9 § 63,

and the common law of Vermont. Specifically, but without limitation, the aforementioned practices
violate Vt. Stat. Ann. tit. 9 § 2453.
202.

Plaintiff State o f Virginia repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
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203.

The aforementioned practices by Defendants were in violation o f Virginia Antitrust Act,

Va. Code §§ 59.1-9.1 et seq. The Commonwealth o f Virginia represents consumers' claims pursuant
to the Attorney General's parens patriae authority.
204.

Plaintiff State of Washington repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
205.

Defendants' acts violate Wash. Rev. Code 19.86.010 etseq.

206.

Plaintiff State of West Virginia repeats and realleges each and every allegation contained

in Paragraphs 1 through 96.
207.

Defendants' acts violate the West Virginia Antitrust Act, W.Va. Code § 47-18-1 et

seq . and the West Virginia Consumer Credit and Protection Act, W.Va. Code § 46A-1-101 et seq.
208.

Plaintiff State of Wisconsin repeats and realleges each and every allegation contained in

Paragraphs 1 through 96.
209.

Defendants' acts violate the Wisconsin Trusts and Monopolies Act, Wis. Stats. §

133.03(1) etseq. and the Wisconsin Marketing and Trade Practices Act, Wis. Stats. §§ 100.18,
100.20 et seq.
210.

Plaintiff State of Wyoming repeats and realleges each and every allegation contained in

paragraphs 1 through 96.
211.

Defendants' acts violate Wyo. Stat § § 40-4-101 et seq. and the Wyoming Consumer

Protection Act, Wyo. Stat. §§ 40-12-101 etseq.

XIV.

RELIEF REQUESTED

Accordingly, the Plaintiff States request judgment as follows:
212.

Adjudge and decree that Defendants have engaged in conduct in violation of Sections 1

and 2 o f the Sherman Act, 15 U.S.C. §§ 1 and 2;
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213.

Adjudge and decree that Defendants have engaged in conduct in violation of the state

statutes enumerated in Paragraphs 97 to 211;
214.

Enjoin and restrain* pursuant to federal and state law, the Defendants, their affiliates,

assignees, subsidiaries, successors and transferees, and the officers, directors, partners, agents and
employees, and all other persons acting or claiming to act on their behalf or in concert with them, from
engaging in any conduct, contract, combination or conspiracy, and from adopting or following any
practice, plan, program or device having a similar purpose or effect to the anti-competitive actions set
forth above;
215.

Enter judgment for the Plaintiff States and award all other available equitable relief,

including, but not limited to, restitution and disgorgement, as the Court finds necessary to redress
Defendants' violations of state and federal law and/or the unjust enrichment of the Defendants;
216.

Enter judgment for the Plaintiff States for three (3) times the amount of damages

sustained by the States, their agencies and their entities as purchasers or assignees o f purchasers of
Cardizem CD or its generic equivalents, as allowed by federal law;
217.

Enter judgment for the Plaintiff States of California, Connecticut, Florida, Hawaii,

Kansas, Maine, Massachusetts, Minnesota, Nevada, New Mexico, New York, North Carolina, Rhode
Island, Virginia, Vermont, West Virginia, and Wisconsin against Defendants, jointly and severally, for
three (3) times the amount of damages sustained by the Plaintiff States, their agencies (including medical
reimbursement programs) and their entities as purchasers of Cardizem CD or its generic equivalents, as
allowed by state law;
218.

Enter judgment for the Plaintiff States of Alaska, Arizona, Arkansas, Idaho, Iowa,

Michigan, North Dakota, Oklahoma, Puerto Rico, South Carolina, Utah, Washington, and Wyoming
and for the District of Columbia, against Defendants, jointly and severally, for the amount of damages
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sustained by the States, their agencies (including medical reimbursement programs) and their entities as
purchasers of Cardizem CD or its generic equivalents, as allowed by state law;
219.

Enter judgment for the Plaintiff States against Defendants, j ointly and severally, and

award restitution, or damages or multiple damages sustained by these States, their agencies (including
medical reimbursement programs), their entities and the persons or citizens they represent or on whose
behalf or for whose benefit this suit is brought, for indirect purchases of Cardizem CD or its generic
equivalents, to the full extent permitted by state law;
220.

Enter judgment for the States of Alaska, Arizona, Arkansas, California, Connecticut,

Florida, Hawaii, Idaho, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Nevada, New
Mexico, New York, North Carolina, North Dakota, Puerto Rico, Rhode Island, South Carolina, Utah,
Virginia, Vermont, Washington, West Virginia, Wisconsin and Wyoming against Defendants for the
maximum civil penalties permitted by state law;
221.

On behalf of the State of Kansas, enter judgment for the full consideration or sums paid

by the State and those persons on whose behalf this action is brought;
222.

Award each State the costs of this action, including reasonable attorneys' fees, and,

where applicable, expert fees; and
223.

Grant such other and further rehef as may be just and proper.
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XV.

JURY TRIAL DEMAND

Plaintiffs demand trial by jury pursuant to Rule 38(b) of the Federal Rules o f Civil Procedure on
all issues triable of right by a jury.
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Enclosure A
REBATE AGREEMENT
Between
The Secretary o f Health and Human Services
(hereinafter referred to as "the Secretary11)
and
The Manufacturer Identified in Section XI o f this Agreement
(hereinafter referred to as “the Labeler")

The Secretary, on behalf o f the Department o f Health and Human Services and all States
and the District o f Columbia (except to the extent that they have in force an Individual
State Agreement) which have a Medicaid State Plan approved under 42 U.S.C. section
1396a, and the Labeler, on its own behalf, for purposes o f section 4401 o f the Omnibus
Budget Reconciliation Act o f 1990, Pub. L. No. 101-508, and section 1927 o f the Social
Security Act (hereinafter referred to as "the Act"), 42 U.S.C. 1396s, hereby agree to the
following:
I

DEFINITIONS

The terms defined in this section will, for the purposes o f this agreement, have the
meanings specified in section 1927 o f the Act as interpreted and applied herein:
(a) "Average M anufacturer Price (AMP)” means, with respect to a Covered Outpatient
Drug o f the Manufacturer for a calendar quarter, the average unit price paid to the
Manufacturer for the drug in the States by wholesalers for drugs distributed to the retail
pharmacy class o f trade (excluding direct sales to hospitals, health maintenance
organizations and to wholesalers where the drug is relabeled under that distributor's
national drug code number). Federal Supply Schedule prices are not included in the
calculation o f AMP. AMP includes cash discounts allowed and all other price reductions
(other than rebates under section 1927 o f the Act), which reduce the actual price paid. It is
calculated as a weighted average o f prices for all the Manufacturer's package sizes for each
Covered Outpatient Drug sold by the Manufacturer during that quarter. Specifically, it is
calculated as Net Sales divided by numbers o f units sold, excluding free goods (i.e. drugs
or any other items given away, but not contingent on any purchase requirements). For
Bundled Sales, the allocation o f the discount is made proportionately to the dollar value o f
the units o f each drug sold under the bundled arrangement. The Average Manufacturer
Price for a quarter must be adjusted by the Manufacturer if cumulative discounts or other
arrangements subsequently adjust the prices actually realized.
(b) "Base Consumer Price Index-Urban (CPI-UV is the CPI-U for September, 1990. For
drugs approved by FDA after October 1, 1990, "Base CPI-U" means the CPI-U for the
month before the month in which the drug was first marketed.
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fc) "Base Date AMP" means the AMP for the 7/1/90-9/30/90 quarter for purposes of
computing the AMP as o f 10/1/90. For drugs approved by FDA after October 1, 1990,
"Base Date AMP" means the AMP for the first day o f the first month in which the drug
was marketed. In order to meet this definition, the drug must have been marketed on that
first day. If the drug was not marketed on that first day, "Base Date" means the AMP for
the first day o f the month in which the product was marketed for a full month.
id) "Best Price" means, with respect to Single Source and Innovator Multiple Source
Drugs, the lowest price at which the manufacturer sells the Covered Outpatient Drug to
any purchaser in the United States in any pricing structure (including capitated
payments), in the same quarter for which the AMP is computed. Best price includes
prices to wholesalers, retailers, nonprofit entities, or governmental entities within the
States (excluding Depot Prices and Single Award Contract Prices o f any agency of the
Federal Government). Federal Supply Schedule prices are included in the calculation of
the best price.
The best prices shall be inclusive o f cash discounts, free goods, volume discounts, and
rebates, (other than rebates under Section 1927 o f the Act).
It shall be determined on a unit basis without regard to special packaging, labeling or
identifiers on the dosage form or product or package, and shall not take into account
prices that are Nominal in amount. For Bundled Sales, the allocation o f the discount is
made proportionately to the dollar value o f the units o f each drug sold under the bundled
arrangement. The best price for a quarter shall be adjusted by the manufacturer if
cumulative discounts, rebates or other arrangements subsequently adjust the prices
actually realized.
(eV'Bundled Sale" refers to the packaging o f drugs o f different types where the condition
of rebate or discount is that more than one drug type is purchased, or where the resulting
discount or rebate is greater than that which would have been received had the drug
products been purchased separately.
(f) "Consumer Price Index-Urban CCPI-UV1 means the index o f consumer prices
developed and updated by the U.S. Department o f Commerce. As referenced in section
1927(c) o f the Act, it is the CPI for all urban consumers (U.S. Average) and, except for
the base CPI-U, it shall be the index for the month before the beginning of the calendar
quarter for which the rebate is made.

( g) "Covered Outpatient Drug" will have the meaning as set forth in Section
1927(k)(2),(k)(3) and (k)(4) o f the Act, and with respect to the Manufacturer includes all
such drug products meeting this definition. For purposes o f coverage under this
agreement, all o f those Covered Outpatient Drugs are identified by the Manufacturer's
labeler code segment of the NDC number. Certain Covered Outpatient Drugs, such as
specified by Section 1927 (d) ( 1) (3) o f the Act, may be restricted or excluded from
Medicaid payment at State option but shall be included by the Manufacturer for purposes
of this agreement.
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ftp "Depot Price" means the price(s) available to any depot o f the federal government, for
purchase o f drugs from the Manufacturer through the depot system o f procurement.
(i) "Health Care Financing Administration fHCFAV' means the agency of the Department
o f Health and Human Services having the delegated authority to operate the Medicaid
Program.
ii) "Individual State Agreement" means an agreement between a State and a
Manufacturer authorized or approved by HCFA as meeting the requirements specified in
Section 1927(a)(1) or (a)(4) o f the Act. Amendments or other changes to agreements
under 1927(a)(4) shall not be included in this definition unless specifically accepted by
HCFA.
An existing agreement that met these requirements as o f the date o f enactment o f P.L.
No. 101-508 (November 5, 1990), can be modified to give a greater rebate percentage.
(k) "Innovator Multiple Source Drug” will have the meaning set forth in Section
1927(k)(7)(A)(ii) o f the Act and shall include all Covered Outpatient Drugs approved
under a New Drug Application (NDA), Product License Approval (PLA), Establishment
License Approval (ELA) or Antibiotic Drug Approval (ADA). A Covered Outpatient
Drug marketed by a cross-licensed producer or distributor under the approved NDA shall
be included as an innovator multiple source drug when the drug product meets this
definition.
(l) "Manufacturer" will have the meaning set forth in Section 1927(k)(5) of the Act
except, for purposes of this agreement, it shall also mean the entity holding legal title to
or possession o f the NDC number for the Covered Outpatient Drug.
(m) 11Marketed*’means that a drug was first sold by a manufacturer in the States after
FDA approval.
(ri) "Medicaid Utilization Information" means the information on the total number of
units o f each dosage form and strength of the Manufacturer's Covered Outpatient Drugs
reimbursed during a quarter under a Medicaid State Plan. This information is based on
claims paid by the State Medicaid Agency during a calendar quarter and not drugs that
were dispensed during a calendar quarter (except it shall not include drugs dispensed
prior to January 1, 1991). The Medicaid Utilization Information to be supplied
includes: 1) NDC number; 2) Product name; 3) Units paid for during the quarter by
NDC number; 4) Total number of prescriptions paid for during the quarter by NDC
number; and 5) Total amount paid during the quarter by NDC number. A State may, at
its option, compute the total rebate anticipated, based on its own records, but it shall
remain the responsibility o f the labeler to correctly calculate the rebate amount based on
its correct determination o f AMP and, where applicable, Best Price.
(o) "National Drug Code (NDCY1is the identifying drug number maintained by the
Food and Drug Administration (FDA). For the purposes o f this agreement the complete

3

11 digit NDC number will be used including labeler code (which is assigned by the
FDA and identifies the establishment), product code (which identifies the specific
product or formulation), and package size code. For the purposes o f making Rebate
Payments, Manufacturers must accept the NDC number without package size code from
States that do not maintain their records by complete NDC number.
fp) "Net Sales" means quarterly gross sales revenue less cash discounts allowed and all
other price reductions (other than rebates under section 1927 of the Act) which reduce
the actual price paid; and as further defined under the definition o f AMP.
(q) "New Drug’1means a Covered Outpatient Drug approved as a new drug under
section 201(p) o f the Federal Food, Drug, and Cosmetic Act.
(r) "New Drug Coverage11 begins with the date o f FDA approval o f the NDA, PLA,
ELA or ADA, for a period of six months from that date, with the exception o f drugs not
under the rebate agreement or classes o f drugs States elect to exclude.
(s) "Nominal Price", for purposes o f excluding prices from the Best Price calculation,
means any price less than 10% o f the AMP in the same quarter for which the AMP is
computed.
ft) "Noninnovator Multiple Source Drug" shall have the meaning as set forth in Section
1927(k)(7)(A)(iii) o f the Act. It also includes Covered Outpatient Drugs approved
under an ANDA or AADA.
(u) “Quarter” means calendar quarter unless otherwise specified.
fv) "Rebate Payment11means, with respect to the Manufacturer's Covered Outpatient
Drugs, the quarterly payment by the Manufacturer to the State Medicaid Agency,
calculated in accordance with section 1927 o f the Act and the provisions o f this
agreement. The terms "Base CPI-U" and "Base Date AMP" will be applicable to the
calculations under 1927(c).
fw) “Secretary” means the Secretary of the United States Department o f Health and
Human Services, or any successor thereto, or any officer or employee of the Department
o f Health and Human Services or successor agency to whom the authority to implement
this agreement has been delegated.
fx) "Single-Award Contract" means a contract between the Federal Government and a
Manufacturer resulting in a single supplier for a Covered Outpatient Drug within a class
o f dmgs. The Federal Supply Schedule is not included in this definition as a single award
contract.
fv) "Single-Award Contract Price" means a price established under a Single-Award
Contract.
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(z) "Single Source Drug" will have the meaning set forth in Section 1927 (k) (7) (A) (iv)
of the Act. It also includes a Covered Outpatient Drug approved under a PL A, EL A or
ABA.
(aa) "States*1means the 50 states and the District o f Columbia.
fbb) "State Medicaid Agency" means the agency designated by a State under Section
1902(a)(5) o f the Act to administer or supervise the administration o f the Medicaid
program.
fee) "Unit" means drug unit in the lowest identifiable amount (e.g. tablet or capsule for
solid dosage forms, milliliter for liquid forms, gram for ointments or creams). The
Manufacturer will specify the unit associated with each Covered Outpatient Dmg, as part
o f the submission o f data, in accordance with the Secretary’s instructions provided
pursuant to Appendix A.
fdd) "Unit Rebate Amount” means the unit amount computed by the Health Care
Financing Administration to which the Medicaid utilization information may be applied
by States in invoicing the Manufacturer for the rebate payment due.
fee) "Wholesaler" means any entity (including a pharmacy or chain of pharmacies) to
which the labeler sells the Covered Outpatient Drug, but that does not relabel or
repackage the Covered Outpatient Drug.
II

MANUFACTURER'S RESPONSIBILITIES

In order for the Secretary to authorize that a State receive payment for the Manufacturer's
drugs under Title XIX of the Act, 42 U.S.C. Section 1396 et seq., the Manufacturer
agrees to the following:
(a) To calculate and, except as provided under section V(b) o f this agreement, to make a
Rebate Payment to each State Medicaid Agency for the Manufacturer's Covered
Outpatient Drugs paid for by the State Medicaid Agency during a quarter.
A separate listing o f all Covered Outpatient Drugs and other information, in accordance
with HCFA's specifications pursuant to Appendix A, must be submitted within 30
calendar days o f entering into this agreement and be updated quarterly.
The
Manufacturer's quarterly report is to include all new NDC numbers and continue to list
those NDC numbers for drugs no longer marketed,
(b) Except as provided under V(b), to make such rebate payments for each calendar
quarter within 30 days after receiving from the State the Medicaid Utilization Information
defined in this agreement. Although a specific amount o f information has been defined
in I(n) o f this agreement, the Manufacturer is responsible for timely payment o f the
rebate within 30 days of receiving, at a minimum, information on the number of units
paid, by NDC number.
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(c) To comply with the conditions of 42 U.S.C. section 1396s, changes thereto and
implementing regulations as the Secretaiy deems necessary and specifies by actual prior
notice to the manufacturer.
(d) That rebate agreements between the Secretary and the Manufacturer entered into
before March 1, 1991 are retroactive to January 1, 1991. Rebate agreements entered into
on or after March 1, 1991 shall be effective the first day o f the calendar quarter that
begins more than 60 days after the date the agreement is entered into.
(e) To report to the Secretary, in accordance with specifications pursuant to Appendix A,
that information on the Average Manufacturer Price and, in the case o f Single Source and
Innovator Multiple Source Drugs, the Manufacturer's Best Price for all Covered
Outpatient Drugs. The Manufacturer agrees to provide such information within 30 days
of the last day o f each quarter beginning with (1) the January 1, 1991-March 31, 1991
quarter or (2) the quarter in which any subsequent effective date o f this agreement lies.
Other information in Appendix A shall also be required within 30 days o f the last day of
the quarter. Adjustments to AMP or Best Price for prior quarters shall also be reported on
this quarterly basis.
(f) In the case of Single Source and Innovator Multiple Source drugs, to report to the
Secretary, in a manner prescribed by the Secretary, the information in Appendix A on the
Base Date AMP. The Manufacturer agrees to provide such information within 30 days of
the date o f signing this agreement.
(g) To directly notify the States o f a New Drug's Coverage.
(h) To continue to make a Rebate Payment on all o f its Covered Outpatient Drugs for as
long as an agreement with the Secretary is in force and State Medicaid Utilization
Information reports that payment was made for that drug, regardless o f whether the
Manufacturer continues to market that drug. If there are no sales by the Manufacturer
during a quarter, the AMP and Best Price last reported continue to be used in calculating
rebates.(i)
(i) To keep records (written or electronic) o f the data and any other material from which
the calculations o f AMP and Best Price were derived. In the absence of specific guidance
in section 1927 o f the Act, Federal regulations and the terms o f this agreement, the
Manufacturer may make reasonable assumptions in its calculations of AMP and Best
Price, consistent with the intent o f section 1927 o f the Act, Federal regulations and the
terms o f this agreem ent A record (written or electronic) outlining these assumptions
must also be maintained.
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Ill

SECRETARY'S RESPONSIBILITIES

(a) The Secretary will use his best efforts to ensure that the State agency will report to
the Manufacturer, within 60 days o f the last day o f each quarter, and in a manner
prescribed by the Secretary, Medicaid Utilization Information paid for during the quarter.
(b) The Secretary may survey those Manufacturers and Wholesalers that directly
distribute their covered outpatient drugs to verify manufacturer prices and may impose
civil monetary penalties as provided in section 1927(b)(3)(B) o f the Act and IV o f this
agreement.
(c) The Secretary may audit Manufacturer calculations of AMP and Best Price.
IV

PENALTY PROVISIONS

(a) The Secretary may impose a civil monetary penalty under 111(b), up to $100,000 for
each item, on a wholesaler, manufacturer, or direct seller of a Covered Outpatient Drug,
if a wholesaler, manufacturer or direct seller o f a Covered Outpatient Drug reiuses a
request for information about charges or prices by the Secretary in connection with a.
survey or knowingly provides false information. The provisions of section 1128A o f the
Act (other than subsection (a) (with respect to amounts o f penalties or additional
assessments) and (b)) shall apply as set forth in section 1927(b)(3)(B).
(b) The Secretary may impose a civil monetaiy penalty, in an amount not to exceed
$100,000, for each item of false information as set f o r i in 1927(b)(3)(C)(ii).
(c) The Secretary may impose a civil monetary penalty for failure to provide timely
information on AMP, Best Price or Base Date AMP. The amount o f the penalty shall be
increased by $10,000 for each day in which such information has not been provided, as
set forth in 1927(b)(3)(C)(i).
V

DISPUTE RESOLUTION - MEDICAID UTILIZATION INFORMATION

(a) In the event that in any quarter a discrepancy in Medicaid Utilization Information is
discovered by the Manufacturer, which the Manufacturer and the State in good faith are
unable to resolve, the Manufacturer will provide written notice o f the discrepancy, by
NDC number, to the State Medicaid Agency prior to the due date in 11(b).
(b) If the Manufacturer in good faith believes the State Medicaid Agency’s Medicaid
Utilization Information is erroneous, the Manufacturer shall pay the State Medicaid
Agency that portion o f the rebate amount claimed which is not disputed within the
required due date in II (b). The balance due, if any, plus a reasonable rate of interest as
set forth in section 1903(d)(5) o f the Act, will be paid or credited by the Manufacturer or
the State by the due date o f the next quarterly payment in 11(b) after resolution o f the
dispute.
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(c) The State and the Manufacturer will use their best efforts to resolve the discrepancy
within 60 days o f receipt of such notification. In the event that the State and the
Manufacturer are not able to resolve a discrepancy within 60 days, HCFA shall require
the State to make available to the Manufacturer the State hearing mechanism available
under the Medicaid Program (42 Code o f Federal Regulations section 447.253 (c)).
(d) Nothing in this section shall preclude the right o f the Manufacturer to audit the
Medicaid Utilization Information reported (or required to be reported) by the State. The
Secretary shall encourage the Manufacturer and the State to develop mutually beneficial
audit procedures.
(e) Adjustments to Rebate Payments shall be made if information indicates that either
Medicaid Utilization Information, AMP or Best Price were greater or less than the
amount previously specified.
(f) The State hearing mechanism is not binding on the Secretary for purposes o f his
authority to implement the civil money penalty provisions of the statute or this
agreement.
VI______________ DISPUTE RESOLUTION - PRESCRIPTION DRUGS ACCESS
AND STATE SYSTEMS ISSUES
(a) A State's failure to comply with the dmg access requirements of section 1927 o f the
Act shall be cause for the Manufacturer to notify HCFA and for HCFA to initiate
compliance action against the State under section 1904 of the Act. A request for
compliance action may also occur when the Manufacturer shows a pattern or history o f
inaccuracy in Medicaid Utilization Information.
(b) Such compliance action by HCFA will not relieve the Manufacturer from its
obligation o f making the Rebate Payment as provided in section 1927 o f the Act and this
agreement.
VII

CONFIDENTIALITY PROVISIONS

(a)
Pursuant to Section 1927(b)(3)(D) o f the Act and this agreement, information
disclosed by the Manufacturer in connection with this Agreement is confidential and, not
withstanding other laws, will not be disclosed by the Secretaiy or State Medicaid Agency
in a form which reveals the Manufacturer, or prices charged by the Manufacturer, except
as necessary by the Secretary to carry out the provisions o f section 1927 o f the Act, and
to permit review under section 1927 o f the Act by the Comptroller General.
(b) The M anufacturer will hold State Medicaid Utilization Information confidential. If
the Manufacturer audits this information or receives further information on such data,
that information shall also be held confidential. Except where otherwise specified in the
Act or agreement, the Manufacturer will observe State confidentiality statutes,
regulations and other properly promulgated policy.
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(c) Notwithstanding the nonrenew al or termination o f this Agreement for any reason,
these confidentiality provisions w ill remain in full force and effect.
VIII_____________NONRENEW AL AND TERMINATION
(a) Unless otherwise term inated by either party pursuant to the term s o f this Agreement,
the Agreement shall be effective for an initial period o f one year beginning on the date
specified in section 11(d) o f this agreem ent and shall be autom atically renewed for
additional successive terms o f one year unless the Labeler gives w ritten notice o f intent
not to renew the agreement at least 90 days before the end o f the current period.
(b) The M anufacturer may term inate the agreem ent for any reason, and such term ination
shall become effective the later o f the first day o f the first calendar quarter beginning 60
days after the M anufacturer gives w ritten notice requesting term ination, or the ending
date o f the term o f the agreement if notice has been given in accordance with VII(a).
(c) The Secretary m ay term inate the Agreement for violations o f this agreem ent or other
good cause upon 60 days prior w ritten notice to the M anufacturer o f the existence o f such
violation or other good cause. The Secretary shall provide, upon request, a M anufacturer
with a hearing concerning such a termination, but such hearing shall not delay the
effective date o f the term ination.
(d) I f this rebate agreement is nonrenewed or term inated, the M anufacturer is prohibited
from entering into another rebate agreem ent as provided in section 1927(b)(4)(C) o f the
A ct until a period o f one calendar quarter has elapsed from the effective date o f the
term ination, unless the Secretary finds good cause for earlier reinstatem ent.
(e) Any nonrenewal or term ination w ill not affect rebates due before the effective date o f
term ination.
IX ________ GENERAL PROVISIONS
(a) Any notice required to be given pursuant to the terms and provisions o f this
A greem ent will be sent in writing.
N otice to the Secretary will be sent to:
Center for M edicaid and State Operations
Family and Children’s H ealth Programs Group
Division o f Benefits, Coverage and Payment
Post Office Box 26686
Baltim ore, MD 21207-0486
N otices to HCFA concerning data transfer and inform ation systems issues are to be sent
to:
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Center for M edicaid and State Operations
Finance, Systems and Quality Group
D ivision o f State Systems
Post Office Box 26686
Baltim ore, MD 21207-0486
The HCFA address may be updated upon written notice to the M anufacturer.
N otice to the M anufacturer will be sent to the address as provided w ith this agreement
and updated upon M anufacturer notification to HCFA at the address in this agreement.
(b) In the event o f a transfer in ownership o f the M anufacturer, this agreem ent is
autom atically assigned to the new ow ner subject to the conditions specified in section
1927 and this agreement.
(c) N othing in this Agreement will be construed to require or authorize the commission
o f any act contrary to law. If any provision of this Agreement is found to be invalid by a
court o f law, this Agreement will be construed in all respects as if any invalid or
unenforceable provision were elim inated, and w ithout any effect on any other provision.
(d) N othing in this Agreement shall be construed as a waiver or relinquishm ent o f any
legal rights o f the M anufacturer or the Secretary under the Constitution, the Act, other
federal laws, or State laws.
(e) The rebate agreem ent shall be construed in accordance with Federal common law
and am biguities shall be interpreted in the m anner which best effectuates the statutory
scheme.
(f) The term s "State M edicaid. Agency" and "M anufacturer" incorporate any contractors
which fulfill responsibilities pursuant to the agreement unless specifically provided for in
the rebate agreem ent or specifically agreed to by an appropriate HCFA official.
(g) Except for the conditions specified in 11(c) and IX(a), this Agreem ent will not be
altered except by an am endment in writing signed by both parties. No person is
authorized to alter or vary the term s unless the alteration appears by way o f a w ritten
am endm ent, signed by duly appointed representatives o f the Secretary and the
M anufacturer.
(h) In the event that a due date falls on a weekend or Federal holiday, the report or other
item w ill be due on the first business day following that weekend or Federal holiday.
X

APPENDIX

Appendix A attached hereto is part o f this agreement.
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XI

SIGNATURES

FOR THE SECRETARY OF HEALTH AND HUMAN SERVICES

Title:

Deputy Director
Finance, Systems and Q uality Group
Center for M edicaid and State Operations
Health Care Financing A dm inistration
Departm ent o f Health and Human Services

D ate:_______________________________________

ACCEPTED FOR THE M ANUFACTURER
I certify that I have made no alterations, amendments or other changes to this rebate
agreement.
B y :____________________________________________
T itle :__________________________________________
N am e o f M anufacturer:________________________________
M anufacturer A ddress____________________________

M anufacturer Labeler Code(s):
D ate:______________________

11

UNITED STATES DISTMCT COURT’
EÀSTERN DISTRIC I OF MICHIGAN
Southern Divistoli
)
IN RE CARDIZEM CD ANTITRUST
LITIGATI QN

)
)

MASTER FILENO. 99-M LM 278
MDL DOCK ET NO. 1278

_________________________ ___________

)

THIS DOCUMENT RELATES TO:

)
)

Hon. Nancy G. Edmunds

Hilly Joe Lightuer, etal. v. Hoechst AXi.,
el uL E.D. Mich, No. 99-CV-7.5070
fM.R, Ala. Nq. 2:<H-T-?54)

Sunshine Pharmacy o f NY v. Hoechst A.G.,
el at., K.D. Mich. No. 99-CV.73S45
(H.D.N.Y. No. 99-CV-1Ó41J

Retwr, Inc. d a l ir. fleuchst4.G.. ft»!.,
B.D. Mich. No. 9'J-i:V-73421

Joseph D aspo sita, et al. v. Hoechst A.G.,
dal., E.D. Mitili. No. 99-CV-73713
(S.D.N.Y, Mn. ì)9-CV-2ì)8S)

(Ni>. Cal, Nu. &5W-CV-3ft<W)

Aetna tf.fi. Healthcare, 0;^,, <?(al v. Hoechst
A. tl, etal.v K.IÏ. Mich. No. 99-CV-734L2
(N.D.Cul. Nû.3:9K-ÇV-4?29)

Shirìetm dover, et al v. fiacchiti A.G.r et al,

GaHoivay, ¡no., etal. v Hoechst ,4.G . ci cl..
ti.D. Mivh, No Îy-CV-73S7l
(S.D. Cal. 99-CV-0645TW)

Eugenio H'ymcSamx v. Hoechst A.ü.r et al.,
E.D. Mich. No. 99-CV-73190
(E.D. Tern. No. 2;98*CV-34ft)

Adna US fiaultftcurv. Inc, y. Hacdtsi A.G..
dai.,V..ïi. Mich. No. 99.CV.74262
No. l:9 9 .f:u m )

L<my S. Sizemore v. Hoechst A.G., et al,
E.D. Mich. No. 99-CV-7334*
(MÜ Tenn. No. 3;9i>-CV-42)

Jùn Gabriel v, Htfcchri if G., CI ctl,
B. D. Mich. No. yy-CV^lili?
(N.D. ill. No. J-9S-CV-7I47)

Albert Etrlch v. Hoechst A.Ü., et al..
(E.D. Wii. 2:£>8-CV-HG7j

Chartesy.uçcawi, dal, v. Hoechst A,G„
et at., K. 17. Mich. Nn, 98-CV-74Q43

Uniteti Wisconsin Services, Ine., et al, v. Hoechst
A,G„ d al, E.D. Mieli. No. 99-CV-73Ö66

E.D. Sfioh. No. 99-CV-74Ì77
(W.D N c. No. 3;99'CV'UÛL69)

E D. Mich. No. 99-CV-7J981

(K.D. Wis.No. 99-CV'389J
Aetna US, Healthcare, Inc. v. Hoechst
t>1al., E.D Mich, No. 99-CV-73239
(□. Mifiii No. 0:99-CV-124)

Marshall J. Ross. v. Hoechst Marion Roussel, Inc., et al,
E.D. Mich. No. Oi-CV-70490
(D. Mat^.Nu. ÛÛ-123J2-JLT)

Mate qf .Ve'*' York, et al. v. Aveulis, SA., et al,
E.D. Midi. No. 01-CV-7I835

FINAL JUDGMENT AND ORDER CERTIFYING SETTLEMENT CLASS,
APPROVING PROPOSED SETTLEMENT AND DISMISSING ACTIONS
Pursuant to Rules 23(e) and 54 of the Federal Rules of Civil Procedure, and in
accordance with (he terms of (he Seulement Agreement entered int» as o f January 2 4 ,2ÛÛ3, it is
hereby ORDERED, ADJUDGED and DECREED:
I.

This Final Judgment and Order o f Dismissal hereby incorporates by reference the

definitions in the Settlement Agreement among the parties to these actions on fife with tins .
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Court, and all capitalized terms used and not otherwise defined herein shall have the meanings
set forth in the Settlement Agreement.
2.

The Court lias jurisdiction over these actions and over each of the Parlies and over

all members o f the Settlement Class.
3.

Thé Notices o f Settlement (in the form presented to this Court as Attachment H to

the Settlement Agreement and Exhibit A to Plaintiffs' motion in support o f preliminary approval
o f (he settlement (the "Preliminary Approval Motion”)) and the Summary Notices o f Settlement
(in the form presented to this Court as Attachment I to the Settlement Agreement anil Exhibit A
to Plaintiffs* iWiminary Approval Motion) (collectively tlic “Notices”) directed to consumer
and Third Party Payer members o f the Settlement Class in accordance with the Notice Plan
submitted to die Court as Exhibit A to Plaintiffs’ Preliminary Approval Motion, constituted the
best notice practicable under (lie circumstances, in making this determination, the Court finds
tliat the Notices and die Notice Plan provided for individual notice to all members o f file
Settlement Class who could be identified through reasonable efforts. Pursuant to, and in
accordance with, Rule 23 o f the Federal Rules o f Civil Procedure, the Court hereby finds that the
Notices and the Notice Plan provided to the members o f the Settlement Class due and adequate
notice o f the Settlement Agreement and these proceedings and the rights o f members o f the
Settlement Class to object to the Settlement Agreement
4.

Pursuant to Rule 23 o f the Federal Rules o f Civil Procedure, this Court hereby

approves the settlement, as set forth in the Settlement Agreement (the “Settlement”), and finds
that file Settlement is, in all respects, fair, reasonable and adequate to the members o f the
Settlement Class. Accordingly, the Settlement shall be consummated in accordance with the
terms and provisions of tire Settlement Agreement
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5.

For purposes of the Settlement and the Settlement Agreement only» the Court

certifies a Settlement Class consisting of;
A13 consumers and Third Parly Payers (including any assignees of
such consumers or Third Party Payers) who purchased and/or paid
all or part o f the purchase price oi'Cardi2em CD Products
dispensed pursuant to prescriptions in the United States (including
Puerto Rico) during the period January 1 , 1998 through the date o f
the Preliminary Approval Order and all Designated Governmental
Agencies. Excluded from the Settlement Class are Idefendants and
any o f their officers and directors, included in the Settlement
Class arc any and all members of any class or classes asserted in
any of the State Actions.
6.

The Court finds that the proposed Settlement Class meets all the requirements o f

Fed. R. Civ. P. 23.
7.

The Court approves Aetna, Inc., Cobalt Corporation and Charles Zuccarmi as

class representatives. In addition to any parens patriae or functionally equivalent authority that
any o f the Attorneys General o f the Plaintiff Stales may have under slate law, the Court further
approves the Attorneys General o f Alaska, Arkansas,

California, Connecticut, Georgia, Indiana,

Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Montana, Nebraska, Nevada, North
Carolina, Oklahoma, South Carolina, Utah, Wisconsin, and Wyoming as additional class
representatives (collectively* with Aetna* Me., Cobalt Corporation and Charles Zuccarini, the
"Class Representatives’") on behalf o f natural person members oflhc Settlement Class residing in
their respective slates.
8.

The Court finds that the below-listed counsel have fairly and adequately

represented the interests o f the Class Representatives arid the members of the Settlement
Class and appoints them as CM-Lead Counsel for the Settlement Class*
Paul Novak, Esq.
Assistant Attorney General
State of Michigan
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Consumer Protection Division, Antitrust Section
G, Mermen Williams Building
525 West Ottawa Street
Lansing, MI 48909
Robert Hubbard, Esq.
Director o f Litigation
Office o f the Attorney General o f the Slate o f New York
Antitrust Bureau
120 Broadway, 26th Floor
New York, NY 10271
Stephen Lowey, Esq, and Richard W. Cohen, Esq.
Lowey Dannenberg ßemporad & Selinger, P.C.
Thu Gateway, 11 th Floor
One North Lexington Avenue
While Plains, NY 1(Hi0l
Joseph J. Tabacco, Jr., Esq.
Herman DeValerio Pease Tabacco Burt & Pucillo
425 California Street, Suite 2025
San Francisco, CA D4104
9,

H ie following actions arc dismissed with prejudice, as provided in die Settlement

Agreement and without costs, except as provided for herein and in the Settlement Agreement:
*

Sunshine Pharmacy o f NY v. Hoechst A. G., et ai, E.D. Mich. No. 99'

*

Joseph D’Esposiio, et ai v. Hoechst A.G.. ei üt,, E.D. Mich* No. 99-

*

Shiriean Glover, et at. v. Hoechst A.G., ela(,t E.D. Mich. No, 99-CV-

CV-73845 (E.D.N.Y. No. 99-CV-I641)
CV-73713 (S.D.N.Y. No. 99-CV-2088)
74377 (W.D.N.C. No. 3;99-CV-U0l69)
*

Eugenia Wynne Sams v. Hoechst A.G., et al-t E.D. Mich. No, 99-CV-

*

Larry S. Sizemore v. Hoechst A.G., ct ai., F„D. Mich. No. 99-CV-

*

Albert Eirick v. Hoechst A.G., et ai., E.D. Mich, No* 99-CV-73981

73190 (E D . Term* No. 2:98-CV-348)
73345 (M .D.Tenn. No. 3:99-CV-42);
(E.D. Wis. 2:9R-CV-1Q27);
*
*
*

United Wisconsin Services, tec., et ai v. Hoechst A.G., ct ai., E D.
Mich* No* 99-CV-73666 (E.D, Wis. No. 99-CV-389);
Marshall J. Ross v. Hoechst Marion Roussel, Inc., et al,, E.D. Mich.
No. 01-CV-70490 (D* Mass. No. 00-123 L2-JLT);
Billy Joe Ughtner, et ai v. Hoechst A.G., et al„ E.D. Mich. No. 99CV-75070 (M.D, Ala, No, 2:99-1-754);
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•
•
•
•
•
•

Beinor, Inc. et al, v. Hoechst A. G.t e.1al., ED . M idi. No. 99-CV73422
(N,D, Cal. No. 3:98-CV-3609);
Aetna US. Healthcare, Inc., eta i v. HoechstA.G-, e t u i E D , Mich.
No. 99-CV-73412 (N.D. Cal. No. 3:98-CV-4729);
Galloway, Inc., etai v. Hoechxt A.G., et al., E.D. Mich. No. 99-CV73871 (S.D, Cal. 99-CV-0645-TW);
Aetna US. Healthcare, Inc. v. Hoechst A.G., et at, E D . Mich, No. 99C V-74262 (D.D.C. No. 1:99-CV-193);
Jan Gabriel v, Haechst A.G., etal.%E.D. Mich. No. 99-CV-73667

■ (N.D. 111. No. U98-CV-7147);
Charles Zuccarini, et al. v. Hoeckst A. G., et al., E.D. Mich, No, 98-

■

C V -74043
■ Aetna US. Healthcare, Inc. v. Hoechst A.G., et al., E.D. Mich. No. 99CV-73239 (D. Minn. No. 0:99-CV-124) and
■ State of New York, et al. v. A vent is, S.A,, et at., E,D, Mich, No, 01-CV71835
10.

Each o f the foregoing dismissals shall become effective upon the date the

Settlement Agreement becomes Effective according to the provisions o f Section T.K o f the
Settlement Agreement. State Law Releasors have covenanted and agreed tliat they shall not
hereafter seek to establish liability or assert Claims* on behalf o f themselves or any other person
or entity, against any o f the State Law Releasees, in whole or in part, for any o f the Released
Claims. Upon (he Effective Date of this settlement, if State Law Releasors, or any member o f
the Settlement Class who has not timely and validly excluded themselves from the Settlement
Class and the settlement, seeks to establish liability or assert any of the Released Claims as set
forth in Section 1T.B of the Settlement Agreement, then this Court or any court o f competent
jurisdiciiOA may enter an injunction restraining prosecution of such proceeding,
11.

On the date that the Settlement Agreement becomes Effective in accordance with

Section i-K of die Settlement Agreement, the State Law Releasors shall release the State Law'
Releasees of the IReleased Claims as set forth in Section H A of the Settlement Agreement,

s

12.

The Court retains exclusivejurisdiction over the Settlement and the Settlement

Agreement as described therein, including the administration and consummation o f tire
Settlement.
13*

Pursuant to Fed. R. Civ. P. 54{b)> there being no just reason for delay, this

judgment o f dismissal shall be entered as final and appealable.

IT IS SO ORDERED,

Dated:
THÈ HwNORAJRLE NANCY EDMUNDS
UNITED STATES DISTRICT JUDGE
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UNITED S T A T E S D ISTRIC T C O U R T
EA ST ER N DISTRICT O F MICHIGAN
SO U TH ER N DIVISION

IN RE: C A R D IZ E M C D ANTITRUST
LITIGATION*

T H IS D O C U M EN T R ELA T ES TO:
ALL ACTIONS,

Master File No. 99-md-1278
M D L No. 1278
Honorable Nancy G, Edmunds

_________ /

SCHEDULING ORDER NO. 48
At a status conference held on October 15, 2003, the Court:
1. Set the following deadlines in the Blue Cross Blue Shield/State Law Individual
Plaintiffs’ Action:
11/12/03 -

Dispositive Motions Due

12/03/03 -

Responses to Dispositive Motions Due

12/17/03 -

Replies to Dispositive Motions Due

01/23/04 -

Oral Argument on Dispositive Motions

2. Scheduled a telephonic status conference to be held on Tuesday, December 2,
2003, at 11:00 a.m.

The parties are to submit a proposed agenda for the status

conference to the Court at least 24 hours before its scheduled date and time fisting all
issues to be discussed and any disputed matters. Liaison counsel, Kathryn Wood,

Dickinson Wright PLLC> shall provide counsel with the appropriate call-in number
S O O R D ER ED ,

Nancy G.Æàmunds
U,S. District Judge

g i o d

m

Dated:
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SETTLEM ENT AGREEM ENT BY AND AM ONG PLA INTIFF STATES, STATE LAW
PLA IN TIFFS. AVENTIS. CARDERM CAPITAL L.P.. AND A N PRX
This Settlement Agreement is made and entered into this 24th day of January, 2003 by and among
the undersigned states and commonwealths, by and through their respective Attorneys General, and the
District o f Columbia, by and through its Corporation Counsel (collectively, the “P lain tiff States”); the
State Law Plaintiffs (as defined below), on behalf o f themselves and in their respective capacities as
representatives of the Settlement Class (as defined below) (collectively with the Plaintiff States,
“P laintiffs”); and Aventis Pharmaceuticals Inc., Carderm Capital L.P., and Andrx Corporation, by and
through their undersigned counsel.

WITNESSETH:
WHEREAS, beginning on August 20,1998, certain consumers and Third Party Payers (as
defined below) filed several lawsuits in state courts around the country alleging that Defendants
monopolized, attempted to monopolize, conspired to monopolize, and entered into agreements that
unreasonably restrained trade in the United States (including Puerto Rico) market for Cardizem® CD
and its generic bioequivalents. Various plaintiffs alleged in these actions that Defendants’ conduct
violated the antitrust, unfair competition and/or consumer protection statutes and the common law of
several states. On June 11,1999, after the cases had been removed to federal courts, the Judicial
Panel on Multidistrict Litigation consolidated these actions in the United States District Court for the
Eastern District o f Michigan; and
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WHEREAS, the State Law Plaintiffs on October 22,1999 filed their First Amended
Coordinated Class Action Complaints against Defendants in the United States District Court for the
Eastern District of Michigan alleging that Defendants monopolized, attempted to monopolize, conspired
to monopolize, and entered into an agreement that unreasonably restrained trade in the market for
Cardizem® CD and its generic bioequivalents in violation o f various state trade practices laws and
common laws prohibiting unjust enrichment, seeking declaratory judgments, restitution for unjust
enrichment, damages, and other equitable relief; and
WHEREAS, on May 14,2001, the Litigating States (as defined below) filed a complaint
against Defendants in the United States District Court for the Eastern District o f Michigan on their own
behalf, on behalf of certain state agencies, and through their statutory, equitable or common law
authority or as representative of or parens patriae on behalf o f natural person citizens of those states,
alleging monopolization, attempted monopolization, and agreement in restraint o f trade in the market for
Cardizem® CD and its generic bioequivalents, in violation of federal and state antitrust, unfair
competition and/or consumer protection laws and seeking injunctive relief, civil penalties, damages,
disgorgement, restitution and other equitable relief; and
WHEREAS, Plaintiffs have conducted extensive economic and factual investigation relating to
the claims, underlying events, and transactions alleged in the Litigating States’ Complaint and the State
Law Plaintiffs5 Coordinated Class Action Complaints (collectively, the “C om plaints’5) and the State
Actions (as defined below), in addition to conducting extensive legal research, and, as a result, the
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Plaintiffs are thoroughly familiar with the liability and damages aspects of the claims they have asserted in
the Complaints and die State Actions; and
WHEREAS, following motion practice, class and merits discovery, class certification of
exemplar classes of certain Michigan consumers and third party payers, and briefing and argument o f an
appeal, extensive arm’s-length negotiations have taken place between counsel for Plaintiffs and counsel
for Defendants in reaching the terms o f this Settlement Agreement with the assistance o f a Courtappointed mediator and economic experts, and Plaintiffs’ counsel have concluded, after extensive
discovery and investigation of the facts and after carefully considering the circumstances o f this litigation,
including the claims asserted in the Complaints and the State Actions and the possible legal and factual
defenses thereto, that it would be in the best interests o f the Plaintiffs and the members o f the Settlement
Class to enter into this Settlement Agreement to avoid the uncertainties of this particularly complex
litigation and to assure a benefit to those represented by the Plaintiffs and to the members of the
Settlement Class, and further, that Plaintiffs’ counsel consider the settlement set forth herein to be fair,
reasonable, and adequate and in the best interests o f the Plaintiffs and the members o f the Settlement
Class; and
WHEREAS, Defendants, while continuing to deny the allegations, any violation o f law or
wrongdoing, and any liability with respect to any and all claims asserted in the Complaints and the State
Actions, have concluded that they will enter into this Settlement Agreement to avoid the further expense,
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inconvenience, and burden o f this protracted litigation, and the distraction and diversion o f their
personnel and resources, and to avoid the risks inherent in uncertain, complex litigation; and
WHEREAS, Defendants deny each and every one o f Plaintiffs’ allegations o f unlawful and
inequitable conduct and Plaintiffs’ entitlement to damages, restitution or any other legal or equitable relief
in connection with Plaintiffs’ claims arising therefrom and have asserted a number of defenses to
Plaintiffs’ claims which Defendants believe to be meritorious; and
WHEREAS, the undersigned have each determined it to be in their respective best interests and
in the best interests o f those whom they represent to resolve this dispute and to enter into this Settlement
Agreement.
NOW, THEREFORE, in consideration o f the mutual covenants and agreements contained
herein, the Parties agree as follows:

I. D EFIN ITIO N S
All terms defined in the preamble to this Settlement Agreement shall be so defined when used
anywhere in this Settlement Agreement Additionally, as used anywhere in this Settlement Agreement:
A.

“A ggregate Settlem ent F und” means the sum of Eighty Million and no/100 Dollars

($80,000,000.00) that Defendants collectively will pay into an Escrow Account pursuant to the terms
and conditions of the Escrow Agreement, in a proportion to which they have agreed and which shall be
disclosed only to the Escrow Agent (in accordance with Sections IV.A. 1., IV.A.2 and VH.A.2(d)) )
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and to no one else in a confidential side letter from Defendants, plus any interest, dividends and other
distributions and payments earned on that sum.
B.

“Andrx” means Defendant Andrx Corporation and its past, present and future

directors, officers, employees, shareholders, affiliates, divisions, predecessors, parents, subsidiaries,
other organizational units o f any kind, general or limited partners, successors, and assigns; and the past,
present and future agents, representatives, attorneys, heirs, executors, administrators, and other persons
acting on behalf o f any of them.
C.

“Aventis” means Defendants Aventis Pharmaceuticals Inc. (formerly known as

Hoechst Marion Roussel, Inc.), Carderm Capital L.P., and their respective past, present and future
directors, officers, employees, shareholders, affiliates, divisions, predecessors, parents (including,
without limitation, Aventis S.A. and Hoechst AG), subsidiaries, other organizational units o f any kind,
general or limited partners, successors, and assigns; and the past, present and future agents,
representatives, attorneys, heirs, executors, administrators, and other persons acting on behalf o f any of
ihem
D.

“Cardizem® CD Products” means Cardizem® CD and/or its AB3 -rated

equivalents.
E.

“Cardizem Protective Order” means (1) the protective order entered in MDL No.

1278 (the “Cardizem Confidentiality Ordei”), and (2) paragraphs 12 and 13 o f Case Management
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Order number 5 (the “Supplemental Confidentiality Order”), true and correct copies o f which are
attached hereto as Attachment K.
F.

“Consumer Distribution Plan” means the plan or method of allocation o f the

Consumer Settlement Fund, which shall be submitted to the Court for approval, and which is annexed
hereto as Attachment E
G.

“Consumer Settlement Fund” means that portion o f the Net Settlement Fund that

will be set aside to pay the administrative costs of such fund and the claims o f natural person members
o f the Settlement Class who paid United States (including Puerto Rico) pharmacies for Cardizem® CD
Products and who file timely and valid proofs of claim.
G(a).

“Consumer Notice Administrator” means the entity or entities appointed by the

Court to administer the Notice Plan and to publish the Notices o f Settlement and the Summary Notices
of Settlement with respect to the consumer members of the Settlement Class.
H.

“Court” means the United States District Court for the Eastern District o f Michigan.

I.

“Defendant” means either Andrx or Aventis. “Defendants” means both Andrx and

Aventis.

J.

“Designated Governmental Agencies” means the Medicaid agencies in any state

and the other governmental agencies listed on Attachment A annexed hereto.
K.

“Effective Date” means the date on which all o f the following conditions shall have

been satisfied, at which time this Settlement Agreement will be deemed to have become “Effective”:
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1.

Receipt by the Escrow Agent of the Aggregate Settlement Fund from
Defendants pursuant to Section IRA o f this Settlement Agreement;

2.

Certification by fixe Court, for settlement purposes only, o f the Settlement Class
without any Material Change;

3.

Entry by the Court o f the Preliminary Approval Order without any Material
Change;

4.

Expiration o f the Opt-Out Deadlines;

5.

No termination o f this Settlement Agreement by Defendants in any manner
permitted and within the time contemplated by this Settlement Agreement
and/or Rider A hereto;

6.

Final approval by the Court of this Settlement Agreement without any Material
Change;

7.

Entry by the Court o f the Final Judgment and Order without any Material
Change;

8.

Either:
(a)

30 days having elapsed following the entry by the Court o f the Final
Judgment and Order, if no notice o f appeal with respect to the Final
Judgment and Order has been timely filed with the Court; or
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(b)

if one or more notices of appeal are timely filed with the Court,
dismissal o f all such appeals or affirmance of the Final Judgment and
Order and this Settlement Agreement in all respects subject to no
further right of review; and

9.

Dismissal o f the State Actions with prejudice without further subsequent
proceedings pursuant to Section V.F with such dismissal to occur within one
hundred eighty (180) calendar days after the last to occur o f the above-enumerated
events.

L.

“Escrow Agent” means the person or entity mutually agreed to and designated by the

Parties in the Escrow Agreement.
M.

“Escrow Agreement” means the escrow agreement, pursuant to which the Aggregate

Settlement Fund shall be administered, without any Material Change to Attachment B annexed hereto,
N.

“Final Judgment and Order” means the Courts final, appealable order, without any

Material Change to Attachment G annexed hereto.

O.

“Government Compensation Plan” means the plan or method o f allocation o f the

State Settlement Fund, which shall be submitted to the Court for approval, and which is adopted and
approved by the Court without any Material Change to Attachment D annexed hereto.
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P.

“Legal Public H oliday” means any day on which the offices o f the Escrow Agent are

closed for the transaction o f public business or designated as a “legal holiday” pursuant to Fed. R. Civ.
P. 6(a), as amended, or any successor to that rule.
Q.

“Litigating S tates” means the States and Commonwealths of Alaska, Arizona,

Arkansas, California, Connecticut, the District o f Columbia, Hawaii, Idaho, Indiana, Iowa, Kansas,
Maine, Michigan, Minnesota, Nevada, New Mexico, New York, North Carolina, North Dakota,
Oklahoma, Puerto Rico, Rhode Island, South Carolina, Utah, Vermont, Washington, W est Virginia,
Wisconsin and Wyoming.
R.

“M aterial C hange” means (a) modification in any manner whatsoever to anything

contained in any o f the following sections o f this Settlement Agreement: Sections I.A through I.W ,
inclusive; Sections II.A through R E , inclusive; Sections IILA, IR B , IR C , and m.D,3; Sections IV.A
and IV.B; Sections V.B, V.C, V.D, and V.F; Sections VI.A,VI.D and VLB; Sections V RA . and
VRB; Sections VIII.A and VERB; Section IX; Sections X.A through X.D, inclusive; and Sections
XI.B, XI.C, XL.H, XEJ and XI.K, Rider A and Attachments B, C, D, G, H, I, and K; or (b) any
modification o f anything else in this Settlement Agreement that affects the terms and scope o f the
releases, covenants not to sue and Released Claims set forth in Sections I.CC, I.FF I.MM, I.NN, II.A
and R B or the State Law Releasees’ ability to assert the releases; or (c) any modification o f anything
else in this Settlement Agreement that affects either the amount o f money paid by the State Law
Releasees pursuant to this Settlement Agreement or any Settlement Reduction set forth in Section IV.A
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and Rider A or the amount o f any Termination Refund in Section X; or (d) any material modification of
anything else in this Settlement Agreement

S.

“MDL No. 1278” means the litigation captioned In Re: Cardizem CD Antitrust

Litigation, Master File No. 99-MD-1278, plus any and all related cases and actions consolidated or
coordinated with that litigation for discovery or other purposes
T.

“MMME Plaintiffs” means Blue Cross Blue Shield o f Michigan, Blue Cross Blue

Shield o f Minnesota, Blue Cross and Blue Shield o f Massachusetts, Inc,, and Excellus Health Plan, Inc.,
the entities that filed suit a^in st Defendants in the United States District Court for the Eastern District of
Michigan on July 26,2001.
U.

“MMME Set-Off” means the pro rata share o f the Third Party Payer Settlement

Fund to which any MMME Plaintiff that timely and validly opts out o f the Settlement Class would have
been entitled to receive if it had filed timely and valid proofs o f claim.
V.

“Net Settlement Fund” means the Aggregate Settlement Fund less: (1) attorneys’

fees, out-of-pocket expenses, and other amounts awarded by the Court to State Law Plaintiffs and/or
their counsel; (2) Court-approved costs o f notice; (3) settlement administration fees and costs with
respect to the Aggregate Settlement Fund that are due and payable to the Escrow Agent pursuant to the
Escrow Agreement; and (4) the State Settlement Fund. Administrative costs for each o f the Settlement
Funds will be allocated to the respective Settlement Fund and will not be deducted from the Aggregate
Settlement Fund.
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W,

“Notices of Exclusion” means the documents annexed hereto as Attachment J.

X.

“Notices of Settlement” means the documents annexed hereto as Attachment H

Y.

“Notice Plan” means the Court-approved process by which the Plaintiffs will publish

the Notices o f Settlement and Summary Notices of Settlement.
Z.

“Opt-Out Deadlines” means both the Consumer Opt-Out Deadline and the Third

Party Payer Opt-Out Deadline as defined below.
Z(a).

“Consumer Opt-Out Deadline” means the date set by the Court as the deadline for

consumer members o f the Settlement Class to file Notices of Exclusion from the Settlement Class.
Z(b).

“Third Party Payer Opt-Out Deadline” means the date set by the Court as the

deadline for Third Party Payer members o f the Settlement Class to file Notices o f Exclusion from the
Settlement Class.
AA.

“Parties” means the State Law Plaintiffs, the Plaintiff States and the Defendants; and

“Party” means any o f them individually.
BB.

“Preliminary Approval Order” means the Court's order preliminarily approving this

Settlement Agreement and preliminarily certifying the Settlement Class, adopted and entered without
any Material Change to Attachment C annexed hereto.
CC.

“Released Claims” means all claims, debts, obligations, damages, liabilities, actions,

proceedings, assertions, and causes o f action (“Claims”), including but not limited to Claims arising
under federal or state antitrust, unfair methods o f competition, or consumer protection laws, under state
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or federal deceptive practices acts, or under common law, whether known or unknown, whether
accrued in whole or in part of any kind whatsoever, from the beginning o f time through the .date this
Settlement Agreement is preliminarily approved by the Court, which any State Law Releasor had, has,
or may in the future have against any State Law Releasee that were or could have been asserted by any
State Law Releasor arising out o f or concerning the allegations, or the facts and circumstances giving
rise to the allegations (including without limitation that certain Stipulation and Agreement, dated
September 24,1997, between Hoechst Marion Roussel, Inc., Carderm Capital L.P. and Andrx
Pharmaceuticals, Inc.), in the Complaints or in any other complaint filed in any action consolidated or
coordinated with MDL No. 1278 or in any State Action, including without limitation all Claims asserted
by any plaintiff in MDL No. 1278.

DD.

“Settlement Administrator of the Consumer Settlement Fund” means that person

or entity appointed by the Court to review, process, and approve the timely filed proofs o f claim of
consumers and to direct the Escrow Agent to pay those claims which are approved pro rata to
consumers entitled to participate in the Consumer Settlement Fund.
EE. “Settlement Administrator of the Third Party Payer Settlement Fund” means that
person or entity appointed by the Court to (i) review, process, and approve the timely filed proofs o f
claim o f Third Party Payers and to direct the Escrow Agent to pay those claims which are approved

pro rata to Third Party Payers entitled to participate in the Third Party Payer Settlement Fund and (ii)
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administer the Notice Plan with respect to Third Party Payer members o f the Settlement Class, and to
publish the Notice o f Settlement and the Summary Notice o f Settlement for Third Party Payers
FF.

“Settlement Class” means, for purposes o f this Settlement Agreement only, all

consumers and Third Party Payers (including any assignees of such consumers or Third Party Payers)
who purchased and/or paid all or part o f the purchase price o f Cardizem® CD Products dispensed
pursuant to prescriptions in the United States (including Puerto Rico) during the period January 1,1998
through the date o f the Preliminary Approval Order and all Designated Governmental Agencies.
Excluded from the Settlement Class are Defendants and any of their officers and directors. Included in
the Settlement Class are any and all members o f any class or classes asserted in any o f the State
Actions,
GG.

“Settlement Fund” means each o f the Aggregate Settlement Fund, the Consumer

Settlement Fund, the State Settlement Fund, and the Third Party Payer Settlement Fund; and

“Settlement Funds” means all of these funds collectively.
HH.

“Settlement Reduction Factor” means fifty percent (50%).

II.

“Settlement Reduction Limit” means Three Million Two Hundred Thousand and

no/100 Dollars ($3,200,000.00).
JJ.

“State Actions” means the actions currently pending in state courts under the following

captions: Pearl Bence Lowy v. Hoechst Aktiengesellschaft et at, Case No. 98-27437-CA (11th
Judicial Circuit Miami-Dade County, Florida); Aetna U.S. Healthcare o f Florida, Inc. v. Hoechst
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Marion Roussel et al, Case No. 00-2461-CA (11th Judicial Circuit Miami-Dade County, Florida);
Aetna U.S. Healthcare, Inc. v. Hoechst Aktiengesellschaft et al, Case No. 99-000200 (District
Court Johnson County, Kansas); and Phillip Neal v. Hoechst Aktiengesellschaft et al, Case No.
99-C-2350 (District Court Johnson County, Kansas).
KK.

“ State Law Plaintiffs” means the plaintiffs in the following actions, all of which were

coordinated under Case No. 99-MD-1278 (Edmunds, J.): Billy Joe Lightner, e ta l v. Hoechst A. G.,

et al, E.D. Mich. No. 99-CV-75070 (M,D. Ala. No. 2:99-T-754); Betnor, Inc. et a l v. Hoechst
A.G., et al, E.D. Mich. No. 99-CV-73422 (N.D. Cal. No. 3:98-CV-3609); Aetna U.S. Healthcare,
Inc., etal. v. Hoechst A.G., etal. , E.D. M ich.N o. 99-CV-73412 (N.D. Cal. No. 3:98-CV-4729);
Galloway, Inc., etal. v. Hoechst A.G., et al, E.D. Mich. No. 99-CV-73871 (S.D. Cal. No. 99CV-0645-TW ); Aetna U.S. Healthcare, Inc. v. Hoechst A. G., e ta l, E.D. Mich. No. 99-CV-74262
(D.D.C. No. 1:99“CV-193); Jan Gabriel v. Hoechst A. G., et al., E.D. Mich. No, 99-CV-73667
(N.D. 111. No. 1:98-CV-7147); Charles Zuccarini, e ta l v. Hoechst A. G., et a l, KD. Mich. No.
98-CV-74043; Aetna U.S Healthcare, Inc. v. Hoechst A.G., et al., E.D. Mich. No. 99-CV-73239
(D. Minn. No. 0:99-CV-124); Sunshine Pharmacy o f New York, Inc . v. Hoechst A. G., et a l, E.D.
Mich. No. 99-CV-73845 (E.D.N .Y .N o. 99-CV -1641); Joseph D'Esposito, et al. v. Hoechst A.G.,

et a l, E.D. Mich. No. 99-CV-73713 (S.D.N.Y. No. 99-CV-2088); Shirlean Glover, et al. v.
Hoechst A.G., et a l, E.D. Mich. No. 99-CV-74377 (W.D.N.C. No. 3:99-CV~00169); Eugenia
Wynne Sams v. Hoechst A.G., et a l, E.D. Mich. No. 99-CV-73190 (E.D. Terni. No. 2:98-CV-
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348); Larry S. Sizemore v. Hoechst A.G., et al., E.D. Mich. No. 99-CV-73345 (M.D. Term. No.
3:99-CV~42); AlbertEirich v. Hoechst A.G., e ta l, E.D. Mich. No. 99-CV-73981 (E.D. Wis.
No. 2;98-CV-1027); United Wisconsin Services, Inc., et al v. Hoechst A.G., et al., E.D. Mich. No,
99-CV-73666 (E.D. Wis. No. 99-CV-389); Marshall J. Ross v. Hoechst Marion Roussel, Inc., et

al,, E.D, Mich. No. 01-CV-70490 (D. M ass. No. 00-12312-JLT); and the plaintiff in the State
Actions.
LL.

“State Law Plaintiffs’ Lead Counsel” means Lowey, Dannenberg, Bemporad &

Selinger, P.C. and Berman DeValerio Pease Tabacco, Burt & Pucillo.
MM.

“State Law Releasees” means the Defendants and their respective past, present and

future directors, officers, employees, shareholders, affiliates, divisions, agents, representatives,
attorneys, heirs, executors, administrators, predecessors, parents, subsidiaries, general or limited
partners, successors, and assigns.
NN.

“State Law Releasors” means:
1.

The Plaintiff States, on behalf o f themselves and, including without limitation:
a.

departments, bureaus, and agencies of Plaintiff States as actual or
alleged purchasers or reim burses;

b.

the Plaintiff States’ quasi-sovereign interests in fair competition and the
health o f their citizenry, and/or in the Plaintiff States’ sovereign
capacities;
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c.

Designated Governmental Agencies; and

d.

Plaintiff States either in their parens patriae or functionally equivalent
capacity, on behalf of natural person members of the Settlement Class
who reside in their respective states, or as class representatives or in a
functionally equivalent capacity, on behalf o f natural person members of
the Settlement Class who reside in their respective states, or as both;
and

2,

The State Law Plaintiffs, on behalf o f themselves and members o f the
Settlement Class, and their respective past, present and future directors,
officers, employees, shareholders, attorneys, heirs, executors, administrators,
general or limited partners, affiliates, divisions, agents, representatives,
predecessors, parents, subsidiaries, agencies, departments, institutions,
successors and assigns.

OO,

“State Liaison Counsel” means the Attorney General o f the State o f Michigan.

PP.

“State Settlement Fund” means that portion o f the Aggregate Settlement Fund that

will be set aside to pay the claims o f the Designated Governmental Agencies, and other remedies as
allowed by state law (which may include civil penalties, restitution and disgorgement claims for
purchases and/or reimbursements o f Cardizem® CD Products). The State Settlement Fund will also
be used to pay the fees and costs o f the Litigating States, subject to Court approval. The amount set
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aside for the State Settlement Fund shall be Seven Million and no/100 Dollars ($7,000,000) plus
interest earned on that amount.

QQ.

“Summary Notices of Settlement” means the documents annexed hereto as

Attachment I.
RR.

“Third Party Payer” or “TPP” means any entity that is (i) a parly to a contract, issuer

of a policy or sponsor o f a plan, and is also (ii) at risk, pursuant to such contract, policy or plan, to
provide prescription drug benefits, or to pay or reimburse all or part o f the cost o f Cardizem® CD
Products dispensed to natural persons covered by such contract, policy or plan.
SS.

“Third Party Payer Distribution Plan” means the plan or method o f allocation of the

Third Party Payer Settlement Fund which shall be submitted to the Court for approval in the form
annexed hereto as Attachment F .
TT.

“Third Party Payer Fund Reduction Amount” means the amount calculated by

(1) subtracting the Third Party Payer Threshold Amount (as defined in Rider A to this Settlement
Agreement) from the Total Third Party Payer Opt-Out Purchases, (2) dividing that remainder by the
Total Third Party Payer Purchases (as defined in Rider A to this Settlement Agreement), (3) multiplying
that quotient by the Aggregate Settlement Fund, and then (4) multiplying that product by the Settlement
Reduction Factor.
UU.

“Third Party Payer Settlement Fund” means that portion o f the Net Settlement

Fund that will be set aside to pay the administrative costs of such fluid and the claims o f Third Party
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Payer members of the Settlement Class which file timely and valid proofs o f claim. As described in
Section IV of this Settlement Agreement, the Third Party Payer Settlement Fund shall be reduced by (1)
any Third Party Payer Fund Reduction Amount, and (2) any MMME Set-O ff.
W .

“Total Third Party Payer Opt-Out Purchases” means the total payments for

prescriptions o f Cardizem® CD filled at retail pharmacies in the United States (including Puerto Rico)
during the period beginning July 1, 1998 and continuing through June 30,1999, inclusive, by TPPs (not
including the MMME Plaintiffs) that execute and file timely and valid Notices o f Exclusion on or before
the Third Party Payer Opt-Out Deadline. A Third Party Payer’s contribution to the Total Third Party
Payer Opt-Out Purchases shall be referred to herein as such entity’s “Opt-Out Purchases.”

n . RELEASES AND COVENANTS
A.

R eleases. Upon the Effective Date o f this Settlement Agreement, the State Law

Releasors, on behalf of themselves and their respective entities and individuals, unconditionally, fully and
finally release and discharge forever the State Law Releasees from the Released Claims and any liability
arising therefrom. The only exception to the foregoing is that if any natural person State Law Plaintiff files a
timely and valid Notice o f Exclusion in his or her personal capacity, such State Law Plaintiff shall be deemed
to not have released any Claims brought solely in his or her individual capacity without affecting in any
manner the Released Claims brought on behalfof any purported class by such State Law Plaintiff, which will
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nonetheless be released as described above. All Released Claims are released and discharged to the fullest
extent o f the law.
B.

Covenant Not to Sue . Each of the State Law Releasors hereby covenants and agrees that

it shall not hereafter seek to establish liability or assert Claims, on behalf o f itself or any other person or
entity, against any of the State Law Releasees, in whole or in part, for any o f the Released Claims.
C.

Additional Release. The State Law Releasors, on behalf of themselves and their

respective entities and individuals, shall also be deemed to have expressly waived, released and forever
discharged any and all provisions, rights and benefits that may be available under:

1.

Section 1542 o f the California Civil Code (“Section 1542”), which provides:
A general release does not extend to claims which tile creditor
does not know or suspect to exist in his favor at the time of
executing the release, which if known by him must have
materially affected his settlement with the debtor;
and

2.

any law of any state or territory o f the United States, or principle o f common
law, which is similar, comparable or equivalent to Section 1542 (each a

“Comparable Law”).
Members o f the Settlement Class shall be advised o f the statutory language o f Section 1542 and the
possible availability o f Comparable Laws in the Notices o f Settlement and, with this understanding,
nevertheless shall elect to and shall assume all risks for Claims heretofore and hereafter arising, whether
known or unknown, suspected or unsuspected, contingent or non-contingent; shall release and forever
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discharge such Claims as part o f the Released Claims; and shall specifically waive any rights they may
have under Section 1542 and any Comparable Law. Members of the Settlement Class shall also be
fully advised that if the facts with respect to which the Releas«! Claims are given and the dismissal with
prejudice contained in the Final Judgment and Order are found hereafter to be other than, or different
from, the facts now believed by them to be true, they shall expressly accept and assume the risk o f such
possible differences and facts, shall expressly waive and fully, finally and forever settle, release and
discharge any such Claims as Released Claims under this Settlement Agreement, and shall agree that the
releases set forth in this Settlement Agreement shall be and remain effective notwithstanding such
differences in facts.
D.

Effect of Releases. This Settlement Agreement may be pleaded as a full and

complete defense to any Action that may be instituted, prosecuted, or attempted with respect to any of
the Released Claims. The State Law Releasors and Defendants further agree that this Settlement
Agreement may be pleaded as necessary for the purpose o f enforcing tins Settlement Agreement.
E.

FTC Reports. Defendants shall provide to the State Liaison Counsel copies o f all

documents and reports required to be provided to the FTC pursuant to Sections V and VI o f that
certain consent order entered in In the Matter o f Hoechst Marion Roussel, Inc. et al., FTC Docket
No. 9293 (May 8,2001), within five (5) business days after such documents and reports are provided
to the FTC. The documents and reports will be subject to the Cardizem Protective Order and shall be
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deemed to have been designated by the Defendants as “Highly Confidential Information” within the
meaning of the Cardizem Protective Order.

m . SETTLEMENT PAYMENTS
A.

Aggregate Settlement Fund: Payment Date. Subject to the terms and conditions o f

this Settlement Agreement and pursuant to the terms o f the Escrow Agreement already executed by the
Parties, Defendants will deposit with the Escrow Agent the aggregate sum o f Eighty Million and no/100
Dollars ($80,000,000.00) plus interest deemed to have begun to accrue on January 2,2003, at the rate
first available to the Escrow Account in full and final settlement and in satisfaction of, and in
consideration o f the covenants contained herein and the release o f the Released Claims.

B.

Payment into Escrow Account. The Aggregate Settlement Fund will be paid, as set

forth below, to the Escrow Agent, to be maintained in an account o f a federally-insured financial
institution (the “Escrow Account”).
C.

Full Satisfaction« The Aggregate Settlement Fund is the total amount that Defendants

will pay under this Settlement Agreement, or in connection with the Complaints and the State Actions,
or in connection with any Released Claim, including, without limitation, attorneys’ fees and costs o f the
State Law Plaintiffs and the Plaintiff States, any Court-approved incentive awards to named Plaintiffs,
and payment o f any and all administrative and notice expenses associated with this litigation or
settlement
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D.

Attorneys’ Fees and Expenses.
1.

State Law Plaintiffs* Lead Counsel State Law Plaintiffs’ Lead Counsel, on
behalf o f all counsel for State Law Plaintiffs, agree to seek an award of
attorneys’ fees not exceeding 17% of the Aggregate Settlement Fund plus
reimbursement o f their itemized out-of-pocket expenses not to exceed Two
Million and no/100 Dollars ($2,000,000,00).

2.

State Attorneys General State Liaison Counsel, on behalf of all counsel for the
Plaintiff States, agrees to seek an award of attorneys’ fees and expenses not
exceeding Two Million Five Hundred Thousand and no/100 Dollars
($2,500,000.00), to be paid exclusively out o f the State Settlement Fund.

3.

Full Satisfaction o f Claims for Attorneys’ Fees. Plaintiffs, members of the
Settlement Class and the Plaintiff States, and their respective counsel, shall not
seek or demand payment o f fees and/or costs beyond those provided for
herein, nor shall they seek payment o f such fees and/or costs from any source
other than the Settlement Funds. All payments o f attorneys’ fees, costs and
expenses contemplated by this Settlement Agreement shall be subject to judicial
approval upon application to the Court and, upon such approval, shall constitute
full and final satisfaction o f any and all claims that any Plaintiff may have or
assert for reimbursement of fees, costs and expenses.
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E.

Incentive Payments. State Law Plaintiffs’ Lead Counsel, on behalf o f State Law

Plaintiffs, agree to seek an award of incentive payments for the role o f State Law Plaintiffs in pursuing
these actions on behalf o f all Settlement Class members, that in aggregate are not in excess of Two
Hundred and Fifty Thousand and no/100 Dollars ($250,000.00).
F.

Allocation of Net Settlement Fund. Plaintiffs have agreed to divide the Net

Settlement Fund as follows:
1.

Consumer Settlement Fund. O f the N et Settlement Fund, 45% shall be
allocated to the Consumer Settlement Fund to pay valid and timely claims of
natural person members o f the Settlement Class who paid for Cardizem® CD
Products.

2.

Third Party Paver Settlement Fund. O f the N et Settlement Fund, 55% shall be
allocated to the Third Parly Payer Settlement Fund to pay valid and timely
claims of Third Party Payer members o f the Settlement Class that paid or
reimbursed all or part of the cost of Cardizem® CD Products and to pay any
Settlement Reduction as described in Section IV o f this Settlement Agreement.

G.

Disposition of Surplus Funds in the Consumer Settlement Fund, I f after

distribution of the settlement proceeds to pay valid and timely claims, monies remain in the Consumer
Settlement Fund, net o f Court-approved costs o f administration and costs o f suit, including reasonable
attorneys’ fees, the remaining amount shall be distributed in a manner and on terms and conditions
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determined by the Court in the exercise o f its reasonable discretion. Such distribution may include,

inter alia., a cy pres distribution to be administered by Plaintiff States to benefit the health care needs of
users o f Cardizem® CD Products, Defendants shall be given written notice of, and a reasonable
opportunity to be heard with respect to, any application requesting the Court’s exercise o f discretion
pursuant to this section.
IV . SETTLEM ENT REDUCTION
A.

, Settlem ent Reduction. The Third Party Payer Settlement Fund shall be subject to the

following potential reductions (each a “ Settlem ent Reduction” ):
1.

MMME Set-Off If any or all of the MMME Plaintiffs timely files valid Notices
o f Exclusion on or before the Third Party Payer Opt-Out Deadline, then,
subject to the terms o f this Settlement Agreement, the Escrow Agent shall pay
to the Defendants the amount o f the MMME Set-Off. Subject to Section IV.B
of this Settlement Agreement, the MMME Set-Off shall be determined by the
Settlement Administrator o f the Third Party Payer Settlement Fund at the time
o f distribution o f the Third Party Payer Settlement Fund, in accordance with the
Third Party Payer Distribution Plan approved by the Court. State Law Plaintiffs
and Defendants shall cooperate in taking discovery from the MMME Plaintiffs
to ascertain the value o f any Opt-Out Purchases attributable to them and the
amount o f the MMME Set-Off The Escrow Agent shall pay to the Defendants
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the amount o f the MMME Set-Off, in the same proportion with which they
contributed to the Aggregate Settlement Fund as described in Section I.A. of
this Settlement Agreement, at the time o f final distribution o f the Third Party
Payer Settlement Fund.
2.

Third Party Paver Fund Reduction Amount. In the event that Total Third Party
Payer Opt-Out Purchases exceed the Third Party Payer Threshold Amount (as
that term is defined in Rider A to this Settlement Agreement), then the Third
Party Payer Settlement Fund shah be reduced by the Third Party Payer Fund
Reduction Amount, up to the Settlement Reduction Lim it Subject to Section
IV.B o f this Settlement Agreement and Rider A hereto, the Third Party Payer
Fund Reduction Amount shall be paid to the Defendants in the same proportion
with which they contributed to the Aggregate Settlement Fund as described in
Section LA. o f this Settlement Agreement, at the time and in the manner
provided in Section VH.B.2 o f this Settlement Agreement.

B.

Determination of Settlement Reductions,
1.

State Law Plaintiffs’ Lead Counsel and counsel for the Defendants shall attempt
in good faith to reach agreement as to the Opt-Out Purchases o f any Third
Party Payer (including any MMME Plaintiff) and/or the amount o f any Third
Party Payer Fund Reduction Amount; and
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2.

If State Law Plaintiffs’ Lead Counsel and counsel for the Defendants fail to
reach agreement concerning any matter described in Section IV.B. 1 within
fifteen (15) calendar days after the Third Party Payer Opt-Out Deadline,
counsel for the Defendants and State Law Plaintiffs’ Lead Counsel shall jointly
cause to be issued against, served on, and enforced against any Third Party
Payer or MMME Plaintiff a subpoena pursuant to Federal Rule of Civil
Procedure 45 requesting documents and/or testimony with respect to its OptOut Purchases and authority to opt-out, provided, however, that nothing herein
shall prevent any o f the Defendants or State Law Plaintiffs from issuing
subpoenae or pursuing discovery from any Third Party Payer or MMME
Plaintiff by any other means prior thereto; and

3.

The Settlement Administrator of the Third Party Payer Settlement Fund shall
calculate the amount of any MMME Set-Off based on the amount and value of
the Opt-Out Purchases attributable to the MMME Plaintiffs determined in the
manner contemplated by this Section IV, and shall promptly thereafter provide
to the Defendants and the State Law Plaintiffs, in accordance with Section
XI.F, written notice (the “Set-Off Notice”) of the amount of the MMME SetO ff so calculated and the method and manner by which it was calculated. The
State Law Plaintiffs and the Defendants, acting through their respective counsel,
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shall provide to the Escrow Agent joint written notice specifying the amount of
such MMME Set-Off and directing payment to the Defendants in the same
proportion with which the Defendants contributed to the Aggregate Settlement
Fund as described in Section I.A o f this Settlement Agreement, at the time for
the final distribution of the Third Party Payer Settlement Fund.
4.

Lithe event o f uncertainty o f the amount o f any Third Party Payer's Opt-Out
Purchases, the Parties shall be bound by the amount o f such purchases as
reflected in the relevant business records o f Aventis which, if different from
those that have already been produced in MDL No. 1278, Aventis will provide
to the Parties subject to the Cardizem Protective Order. In the event that the
business records o f Aventis are incomplete or do not contain sufficient data
necessary to conclusively establish the amount o f any Third Party Payer's OptOut Purchases, the Parties agree to be bound by the business records o f such
Opt-Out Entities, as such records are obtained voluntarily or through judicial
process,

V. N OTICE AND SETTLEM ENT HEARING
A.

M otion for Prelim inary Approval. On or before January 24,2003, State Liaison

Counsel and State Law Plaintiffs’ Lead Counsel shall file with the Court a motion for preliminary
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approval o f the Settlement Agreement and entry o f the Preliminary Approval Order. This motion shall
include this Settlement Agreement and ail attachments hereto. Defendants shall have a reasonable
opportunity to review and comment on the motion papers in advance o f the filing.

B.

Motion To File Rider A Under Seal. The Defendants and State Law Plaintiffs shall

jointly file, contemporaneous with the filing o f the motion for preliminary approval, a motion to file Rider
A to this Settlement Agreement under seal, pending the expiration o f the Third Party Payer Opt-Out
Deadline plus thirty (30) days. The Parties agree that they shall maintain the confidentiality of Rider A to
this Settlement Agreement and the information set forth therein at all times that Rider A is under seal.
The Plaintiff States agree that they will take no position on the motion to file Rider A under seal.
C.

Stay of State Actions. Within ten (10) business days after execution o f this Settlement

Agreement by the designated representatives o f each o f the Parties, counsel for the Defendants and
State Law Plaintiffs shall jointly send motions to the judges presiding over the State Actions advising
them o f this Settlement Agreement and requesting that the State Actions be stayed pending approval of
this Settlement Agreement and the settlement embodied herein.
D.

Implementation of Notice Plan. Within thirty (30) calendar days after entry by the

Court o f the Preliminary Approval Order without any Material Change, State Liaison Counsel and State
Law Plaintiffs’ Lead Counsel shall effectuate the Notice Plan. The Parties will propose staggered
notice periods whereby notice to Third Party Payer members o f the Settlement Class will be made in
advance o f notice to consumer members o f the Settlement Class. The Third Party Payer Opt-Out
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Deadline will also be at least ninety (90) days prior to sending notice to consumer members o f the
Settlement Class. The Parties contemplate that the time between the beginning o f the notice period for
the Third Party Payer members of the Settlement Class and Consumer Opt-Out Deadline will not
exceed two hundred thirty-seven (237) calendar days, or such other reasonable time period as may be
set by the C ourt The Parties will use their reasonable best efforts to have the determinations specified
in Rider A and Section IV.A.2 completed prior to notice being given to consumer members of the
Settlement Class.
E.

Final Hearing. At or before the time set by the Court in the Preliminary Approval

Order for the settlement hearing to consider the final approval of this Settlement Agreement and the
settlement embodied herein, Plaintiffs shall submit papers in support o f the Court’s final approval of this
Settlement Agreement and the settlement embodied herein as fair, reasonable and adequate, and shall
seek enhy by the Court o f the Final Judgment and Order. Each Party shall have a reasonable
opportunity to review and comment on the other Party’s papers in advance o f the filing.
F.

Dismissal of State Actions. Within ten (10) business days following the entty by the

Court o f the Final Judgment and Order without any Material Change,, the Defendants and State Law
Plaintiffs shall jointly move the respective state courts in which the State Actions are pending to dismiss
the State Actions with prejudice on the grounds that such State Actions have been rendered moot, the
Claims therein have been settled, released and barred pursuant to the doctrine o f res judicata , and/or
any other applicable basis.
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VL SETTLEMENT ADMINISTRATION
A.

Investment Authority of Escrow Agent. The Escrow Agent shall invest the

Settlement Funds solely in obligations of, or obligations guaranteed by, the United States o f America or
any of its departments or agencies (which may be held either directly by the Escrow Agent or through
one or more intermediate investment vehicles), and shall reinvest the proceeds o f these instruments as
they mature in similar instruments at their then current market rates. Immediately upon receipt o f the
payment set forth in Section in A, the Escrow Agent shall segregate and invest separately the State
Settlement Fund from the other Settlement Funds.

B.

Appointment of Settlement Administrator of the Consumer Settlement Fund,

Consumer Notice Administrator, Settlement Administrator of the Third Party Paver
Settlement Fund, and Distribution of Settlement Funds. The Settlement Administrator o f the
Consumer Settlement Fund and the Consumer Notice Administrator shall be selected by the State
Liaison Counsel and the Settlement Administrator of the Third Party Payer Settlement Fund shall be
selected by the State Law Plaintiffs’ Lead Counsel, both to be appointed by the Court pursuant to the
Preliminary Approval Order. The State Settlement Fund shall be administered by the State Liaison
Counsel. The Consumer Settlement Fund and the Third Parly Payer Settlement Fund shall be
administered according to the Consumer Distribution Plan and the Third Party Payer Distribution Plan,
and further order o f the Court.
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C.

Court Jurisdiction Over Settlement Funds. All funds held in 1he Aggregate

Settlement Fund, the Consumer Settlement Fund, the Third Party Payer Settlement Fund and the State
Settlement Fund shall be deemed to be in custodia legis, and shall remain subject to the jurisdiction of
the Court, until such Settlement Funds are folly distributed or returned to Defendants, or upon further
order(s) o f the Court.
D.

Tax Treatment of Settlement Funds,
1.

The Settlement Funds shall be treated as being at all times “qualified settlement
funds” within the meaning o f Treas. Reg. § 1.468B-1. The Escrow Agent and,
as required, the Parties, shall timely make such elections as necessary or
advisable to cany out the provisions of this Section VÏ.D, including the
“relation-back election” (as defined in Treas. Reg. § 1.468B-1), back to the
earliest permitted date. Such elections shall be made in compliance with the
procedures and requirements contained in such regulation. It shah be the sole
responsibility of the Escrow Agent to timely and properly prepare and deliver
the necessary documentation for signature by all necessary parties, and
thereafter to cause the appropriate filing to occur.

2.

For the purpose o f Section 468B o f the Internal Revenue Code o f 1986, as
amended, and the regulations promulgated thereunder, the “administrator” shall
be the Escrow A gent The Escrow Agent shall timely and properly file all
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informational and other tax returns necessary or advisable with respect to the
Settlement Funds (including, without limitation, the returns described in Treas.
Reg. § 1,468B-2(k)&(l). Such returns (as well as the election described in
Section VLD. 1) shall be consistent with this Section VI.D and in all events shall
reflect that all taxes (including any estimated taxes, interest or penalties) on the
income earned by the Settlement Funds shall be paid out o f the appropriate
- Settlement Fund as provided in Section VT.D.3.
3.

All (i) taxes (including any estimated taxes, interest or penalties) arising with
respect to the income earned by a Settlement Fund, including any taxes or tax
detriments that may be imposed upon Defendants with respect to any income
earned by a Settlement Fund for any period during which such Settlement Fund
does not qualify as a “qualified settlement fund” for federal or state income tax
purposes (“ T axes”), and (ii) expenses and costs incurred in connection with
the administration of such Settlement Fund and the operation and
implementation o f this Section V1.D (including, without limitation, expenses of
tax attorneys and/or accountants and mailing and distribution costs and
expenses relating to filing (or failing to file) the returns described in this Section
VLD) (“ T ax Expenses”), shall be paid out o f the affected Settlement Fund.
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4.

Taxes and Tax Expenses shall be treated as, and considered to be, a cost of
administration o f the settlement and shall be timely paid by the Escrow Agent
out o f the appropriate Settlement Fund with respect to which such Taxes and/or
Tax Expenses have accrued, without prior order from the Court. The Escrow
Agent shall be obligated (notwithstanding anything herein to the contrary) to
withhold from distribution out o f the appropriate Settlement Fund any funds
necessary to pay such amounts including the establishment o f adequate reserves
for any Taxes and Tax Expenses (as well as any amounts that may be required
to be withheld under Treas. Reg. § 1.468B-2(1)(2)).

5.

The Parties agree to cooperate with the Escrow Agent, each other, and their tax
attorneys and accountants to the extent reasonably necessary to carry out the
provisions o f this Section VI.D. For purposes of this Section VI.D, references
to a Settlement Fund shall include such Settlement Fund and any earnings
thereon.

6.

Nothing in this Section shall be construed to mean that there are any Taxes or
Tax Expenses which will be incurred by the State Settlement Fund.

E.

T.imitation on Defendants* Liability for Transactions Involving Settlement

Funds, The Parties expressly disclaim that Defendants have any responsibility or liability for any
distributions o f the Settlement Funds or interest earned thereon, or any reporting requirements that may
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relate thereto. The Parties agree that no person shall have any claim against any of the Parties, their
respective counsel, the Escrow Agent or any agent designated by the Escrow Agent based on the
distributions made substantially in accordance with this Settlement Agreement and any orders o f the
Court.

V II. SETTLEM EN T DISBURSEM ENTS
A.

Paym ents By th e Escrow A gent. The Escrow Agent shall have the following

responsibilities:
1.

Depositing and investing the Aggregate Settlement Fund into the Escrow
Account; and

2.

Paying out o f the Aggregate Settlement Fund, in accordance with Orders o f the
Court:
(a)

Subject to Section VII.B.1 o f this Settlement Agreement, to the
Settlement Administrator o f the Third Party Payer Settlement Fund,
actual notice and administrative costs reasonably incurred for the
purpose of undertaldng the ftmctions described in Section I.EE

(b)

Subject to Section VH.B.2 of this Settlement Agreement, to the
Consumer Notice Administrator, actual notice costs reasonably
incurred for the purpose o f providing the Notice o f Settlement and the
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Summary Notice o f Settlement to consumer members of the Settlement
Class in accordance with the Notice Plan;
(c)

Subject to Section VÏÏ.B.3 o f this Settlement Agreement, to the
Settlement Administrator o f the Consumer Settlement Fund, the costs
incurred in the administration of the Consumer Settlement Fund;

(d)

To Defendants, the amount o f any Third Party Payer Fund Reduction
Amount, in the same proportion with which they contributed to the
Aggregate Settlement Fund as described in Section I.A. o f this
Settlement Agreement;

(e)

To State Law Plaintiffs’ Lead Counsel, the amount o f State Law
Plaintiffs’ attorneys’ fees and expenses awarded by the Court;

(f)

To any State Law Plaintiff entitled thereto, any incentive payment
awarded by the Court;

(g)

To Plaintiff States, the amount o f the State Settlement Fund, pursuant to
the direction of State Liaison Counsel;

(h)

To the members o f the Settlement Class who or which file timely and
valid proofs o f claim, the approved amount o f such claims;
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(i)

To Defendants, the amount o f any MMME Set-Off, in the same
proportion with which they contributed to the Aggregate Settlement
Fund as described in Section I.A of this Settlement Agreement

3.

Paying any federal, state or local taxes due on the Settlement Funds; and

4.

Paying to the Defendants the Termination Reftrnd following the occurrence o f an
Event o f Termination as those terms are defined in Section X o f this Settlement
Agreement

B.

Timing of Payments By the Escrow Agent. The Escrow Agent shall make the

payments identified in Section VILA and Section X at the following times:
1.

After the Court’s entry o f the Preliminary Approval Order without any Material
Change, the payments identified in Section VII.A.2(a) o f this Settlement
Agreement, as such notice and administrative costs become payable pursuant to
Section 4(b)(i) of the Escrow Agreement. The aggregate amount o f all such
notice and administrative costs that shall be reimbursable with respect to the
Third Party Payer Settlement Fund during the period beginning the day after the
Court’s entry of the Preliminary Approval Order without any Material Change
and ending on the earlier to occur o f (i) the Effective Date, and (ii) February 1,
2004 shall not exceed One Hundred Fifty Thousand and no/100 Dollars
($150,000.00). Beginning on the earlier to occur o f (i) February 2,2004 or (ii)
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the day after the Effective Date, any such notice or administrative costs as shall
be deemed reasonable by the Court shall not exceed the money then available
in die Third Party Payer Settlement Fund (from which such payments shall be
made). The first o f such payments shall be made within five (5) business days
following receipt by the Escrow Agent of joint written notice from the Plaintiffs
and the Defendants, as provided for in Section 4(b)(i) o f the Escrow
Agreement.
2.

After the Court’s entry o f the Preliminary Approval Order without any Material
Change, and after May 1,2003, the payments identified in Section VII.A.2(b)
o f this Settlement Agreement, as such notice costs become payable pursuant to
Section 4(b)(ii) o f the Escrow Agreement. The aggregate amount o f all such
notice costs that shall be reimbursable with respect to the Consumer Settlement
Fund after May 1,2003, shall not exceed One Million Six Hundred Thousand
and no/100 Dollars ($1,600,000.00)(the “Notice Payment”). The first of such
payments shall be made within five (5) business days following receipt by the
Escrow Agent o f joint written notice from the Plaintiffs and the Defendants, as
provided for in Section 4(b)(ii) o f the Escrow Agreement.

3.

After the Court’s entry o f the Preliminary Approval Order without any Material
Change, and after June 1,2003, the payments identified in Section VII.A.2(c)
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o f this Settlement Agreement, as such administrative costs become payable
pursuant to Section 4(b)(iii) o f the Escrow Agreement. The aggregate amount
o f all such administrative costs that shall be reimbursable with respect to the
Consumer Settlement Fund between June 1,2003 and the earlier to occur o f (i)
the Effective Date or (ii) February 1,2004 shall be limited to One Million and
no/100 Dollars ($1,000,000) plus the amount o f the Notice Payment not used
for consumer notice costs. The aggregate amount o f all administrative and
notice costs authorized by Sections VII.A.2(a), VH A .2(b), and VII.A.2(c) o f
this Settlement Agreement that shall be reimbursable prior to the earlier o f (i)
February 2,2004 or (ii) the day after the Effective Date shall not exceed Two
Million Seven Hundred Fifty Thousand and no/100 Dollars ($2,750,000.00),
Beginning on the earlier to occur o f (i) February 2,2004 or (ii) the day after the
Effective Date, any such notice or administrative costs as shall be deemed
reasonable by the Court shall not exceed the money then available in the
Consumer Settlement Fund (from which such payments shall be made). The
first o f such payments for administrative costs shall be made after June 1,2003
and within five (5) business days following receipt by the Escrow Agent o f joint
written notice from the Plaintiffs and the Defendants, as provided for in Section
4(b)(iii) o f the Escrow Agreement.
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4.

In the event that Defendants shall become entitled to a refund o f the Third Party
Payer Fund Reduction Amount (as described in Section VH.A.2(d) of this
Settlement Agreement), the Escrow Agent shall pay that amount to Defendants
as soon as practicable following, but in no event later than five (5) business days
after, receipt by the Escrow Agent of joint written notice from the State Law
Plaintiffs and the Defendants, acting through their respective counsel, advising
the Escrow Agent that the Third Party Payer Fund Reduction Amount has been
determined to be due and payable and o f the amount of the Third Party Payer
Fund Reduction Amount finally determined to be due and payable pursuant to
Section IV o f this Settlement Agreement and directing the Escrow Agent to pay
such amount to the Defendants.

5.

In the event that Defendants shall become entitled to a Termination Refund (as
described and defined in Sections VH.A.4 and X.C o f this Settlement
Agreement), the Escrow Agent shall pay that amount to Defendants at the time
provided in Section X.C.

6,

The payments identified in Sections VII.A.2(e) and VII.A.2(f), promptly
following:
(a)

the later to occur of: (i) the date on which all o f the conditions specified
in Section I.K shall have been satisfied, provided that, solely for
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purposes o f this Section VH,B.6(a), only an appeal initiated by either
Defendant or both Defendants, written notice o f which is provided to
Plaintiffs within ten (10) business days after entry o f the Final Judgment
and Order without any Material Change, shall be deemed to constitute
an appeal contemplated by or affecting the operation o f the conditions
stated in Section I.K.8 of this Settlement Agreement; and (ii) the Court
order awarding these payments; and
(b)

receipt by the Escrow Agent of joint written notice (accompanied by a
copy o f the Court’s order awarding payment thereof) from the Plaintiffs
and the Defendants, acting through their respective counsel, advising the
Escrow Agent that the conditions set forth in Section VT[.B.6(a) have
been satisfied and directing the Escrow Agent to pay the amounts
ordered by the Court, to the extent, in the manner and to the persons
described in the Court’s order;

further provided that, if a final judgment by the Court approving this Settlement
Agreement and the settlement embodied herein is reversed on appeal, State
Law Plaintiffs’ Lead Counsel shall, within five (5) business days after
Defendants shall have provided them with written Notice o f Termination in
accordance with Section X.B, cause a refund to be made to the Aggregate
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Settlement Fund in the amount o f the disbursements previously made to State
Law Plaintiffs’ Lead Counsel and to any Plaintiff pursuant to Sections
VIIA.2(e) and VII.A.2(i) and this Section VILB.6 (plus interest that would
have accrued on that amount had it remained in the Aggregate Settlement Fund)
and shall cause such amount to be repaid to Defendants as part o f the
Termination Refund in accordance with Section X.C.
7.

The payments identified in Sections VH,A.2(g) and VU.A.2(h), within thirty
(30) calendar days following the Effective Date of this Settlement Agreement
and the receipt by the Escrow Agent of joint written notice from the Plaintiffs
and the Defendants, acting through their respective counsel, advising the Escrow
Agent that the Settlement Agreement has become Effective and directing the
Escrow Agent to make these payments.

8,

In the event that Défendante shall become entitled to a refund o f the MMME
Set-Off (as described in Section VII.A.2(i) o f this Settlement Agreement), the
Escrow Agent shall pay that amount to Defendants at the time of final
distribution o f the Third Party Payer Settlement Fund consistent with Section
VII.B(7) o f this Settlement Agreement and following receipt by the Escrow
Agent of joint written notice from the State Law Plaintiffs and the Defendants,
acting through their respective counsel, advising the Escrow Agent that the
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MMME Set-Off has been determined to be due and payable and of the amount
o f the MMME Set-Off finally determined to be due and payable pursuant to
Section IV o f this Settlement Agreement and directing the Escrow Agent to pay
such amount to the Defendants in the same proportion with which they
contributed to the Aggregate Settlement Fund as described in Section LA. of
this Settlement Agreement..

V III. COOPERATION AND IM PLEM ENTATION
A.

R easonable B est E ffo rts. Counsel for the undersigned agree to recommend

approval o f this Settlement Agreement by the Court and to undertake their reasonable best efforts,
including all steps and efforts detailed in this Settlement Agreement and any other steps and efforts that
may be necessary or appropriate, by order o f the Court or otherwise, to expeditiously cany out the
terms o f this Settlement Agreement. The Parties shall have a reasonable opportunity to review any
motion papers in advance o f filing.
B.

Stay o f D iscovery. The Parties agree that all discovery relating to the Released

Claims is stayed.
C.

Public Statem ents. The date and timing o f the initial press releases will be set by

mutual agreement of the Parties.
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IX. BENEFIT AND BINDING EFFECT
The terms of this Settlement Agreement shall he binding on, and shall inure to the benefit of, the
Parties and their successors and assigns. The Parties expressly disclaim any intention to create rights
under this Settlement Agreement that may be enforced by any other person under any circumstances
whatsoever, except as provided in this Settlement Agreement.

X. TERMINATION
Events of Termination, Defendants (jointly but not severally) shall have the right and

A.

the option in their sole discretion to terminate this Settlement Agreement in the event that any of the
following events (each an “Event of Termination”) shall have occurred:
1.

Any condition enumerated in Section I.K o f this Settlement Agreement shall have
failed to occur and this Settlement Agreement shall have failed to become Effective
unless it shall have failed to become Effective because o f the condition enumerated
in Section I.K.1 because o f events directly and solely controlled by the
Defendants; or

2.

A Plaintiff State, State Attorney General or any other person or entity successfully,
validly and timely opts out o f the Settlement Class (i) in a representative capacity
on behalf o f (a) the consumers residing in a state or (b) any class o f persons or
entities; or (ii) is allowed to proceed with any claim, relief or remedy, including
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without limitation disgorgement, on behalf of any others not immediate family
members or persons in direct privity o f contract or a guardian or executor,
executrix, or administrator o f an estate having pre-existing legal authority; or
3.

A Plaintiff, State that has executed this Settlement Agreement subsequently is
permitted to (a) rescind its execution of, (b) renounce, or (c) withdraw from this
Settlement Agreement; or

4.

A Voidable Event (as that term is defined in Rider A to this Settlement Agreement)
shall have occurred.

B.

Exercise of Right of Termination. Following an Event o f Termination, Defendants

may terminate this Settlement Agreement by providing written notice (“Notice of Termination”) to
State Law Plaintiffs’ Lead Counsel and State Liaison Counsel (in accordance with Section XI.F) and to
the Escrow Agent (to the address provided in the Escrow Agreement) within thirty (30) calendar days
following the Defendants’ receipt of actual notice o f such Event of Termination (the “Exercise

Period”). Notice o f Termination will be deemed to have been timely provided to the recipients named
herein upon any o f the following actions occurring within the Exercise Period:
1.

service o f Notice of Termination upon such recipient (if given personally); or

2.

deposit by Defendants o f Notice o f Termination with the courier (if given by
express courier); or
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3.

transmission ofNotice o f Termination to such recipient by facsimile transmission (if
given by facsimile transmission followed by postage prepaid mail).

The Exercise Period shall be subject to extension (a) by the Court for good cause shown or (b) to the
next business day following the end of the Exercise Period (as it may be extended in accordance with
the immediately preceding clause) in the event that the last day of such period falls on a Saturday, a
Sunday or a Legal Public Holiday or (c) by written agreement among the Parties.
C.

Termination Refund. Within ten (10) business days following the date on which

Defendants provide Notice o f Termination in accordance with Section X.B, the Escrow Agent shall
repay to the Defendants the Aggregate Settlement Fund (including interest accrued thereon), less the
sum of: (i) actual notice and administrative costs paid or due and payable limited as described in Section
VII, plus (ii) amounts paid, or due and payable, to the Escrow Agent pursuant to the Escrow
Agreement up to the date o f the Event o f Termination, plus (iii) any accrued tax liability as defined in
Section VI.D.2 (the amount so calculated being the “Termination Refund”). If, prior to the end of
the ten (10) day period specified in this Section X.C., Plaintiffs (jointly but not severally) notify by fax
the Escrow Agent and Defendants that they dispute the Defendants’ right to terminate this Settlement
Agreement for any reason other than the amount o f a Third Party Payer’s Opt-Out Purchases as
provided in Section IV.B.4 o f this Settlement Agreement ("Termination Dispute Notice”), the Escrow
Agent shall not release the Termination Refund to Defendants until thirty days following the receipt o f
notification by Plaintiffs. The Parties agree to attempt to resolve their dispute in good faith during such
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time. In the event that the Parties can not resolve their dispute, the Escrow Agent shall return such funds
to the Defendants, as Defendants have the sole and exclusive right to terminate this Settlement
Agreement pursuant to this Section of the Settlement Agreement without any right on the part o f the
Plaintiffs to challenge, dispute, or appeal such termination.
D.

Effect of Exercise of Termination Rights on Litigation. Upon the timely and valid

exercise by Defendants o f the right to terminate this Settlement Agreement as provided in this Section
X, this Settlement Agreement shall become null and void, shall have no further force and effect, and the
Plaintiff States and State Law Plaintiffs shall retain full rights to assert any and all Claims against State
Law Releasees, and State Law Releasees shall retain any and all defenses thereto. These actions shall
thereupon revert to their respective procedural and substantive status prior to the date of execution
hereof and shall proceed as if this Settlement Agreement, and all other related orders and papers, had
not been executed. In such event, the Parties shall jointly request that any order contemplated hereby,
which shall have been entered, be vacated and that the Court enter an order authorizing the Parties to
resume and complete discovery in these actions.

XI. MISCELLANEOUS
A.

• Entire Agreement. This Settlement Agreement, the attachments hereto and Rider A

to the Settlement Agreement (collectively, the “Settlement Documents”) contain the entire agreement
and understanding o f the Parties. There are no additional promises, understandings or terms o f the
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Settlement Agreement other than those contained herein. The Settlement Documents supersede and
render o f no effect all other oral or written communications concerning the subject matter hereof.
B.

M odification; W aiver.
1.

G enerally. Subject to Section XI.B.2 hereof, the terms or provisions of this
Settlement Agreement may not be changed, waived, modified, or varied in any
manner whatsoever unless in a writing duly signed by all Parties with the consent
o f the Court Any failure by any Party to insist upon the strict performance by
any other Party o f any of the provisions o f this Settlement Agreement shall not
be deemed a waiver of any o f the provisions hereof, and that Party,
notwithstanding that failure, shall have the right thereafter to insist upon the strict
performance of any and all o f the provisions o f this Settlement Agreement to be
performed by the other Party.

2.

A djustm ents to D ates C ertain. In the event that the Third Party Payer OptOut Deadline shall be scheduled to occur on any date after March 14,2003,
the dates occurring after March 14,2003 specified in Sections VH.B.l,
VÏÏ.B.2 and VII.B.3 shall automatically, and without further action o f the Parties
or the Court, be extended by a number o f calendar days equal to the number o f
calendar days by which the Third Party Payer Opt-Out Deadline differs from
March 14,2003. In the event that the Consumer Opt-Out Deadline shall be set
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to occur on any date after September 22,2003, the dates occurring after
September 22,2003 specified in Sections V II.B.l, W .B .2 and VII.B,3 shall
automatically, and without further action o f the Parties or the Court, be
extended by a number o f calendar days equal to the number of calendar days
by which the Consumer Opt-Out Deadline differs from September 22,2003.

C.

Authority. The undersigned counsel for each o f the Parties hereby represents and

warrants that he or she is authorized to enter into this Settlement Agreement on behalf of that Party.
Each o f the Plaintiffs represents and warrants that it has not assigned, and that it shall not assign at any
time on or before the Opt-Out Deadlines, nor shall it attempt or purport to assign after the Opt-Out
Deadlines, any Released Claim or any right, title or interest in any Released Claim, to any person or
entity who is not included among the State Law Releasors. State Liaison Counsel represents and
warrants that its signature on behalf o f a Plaintiff State reflects the authority o f State Liaison Counsel to
bind such Plaintiff State.
D.

No Party is the Drafter. The Settlement Agreement shall be deemed to have been

mutually prepared by the Parties hereto and shall not be construed against any of them solely by reason
o f authorship, ,
E.

Execution in Counterparts. The Settlement Agreement may be executed in one or

more counterparts. All executed counterparts and each o f them shall be deemed to be one and the
same instrument A complete set o f original executed counterparts shall be filed with the Court. This
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Settlement Agreement may be validly executed and delivered by fax or other electronic transmission,

provided that any such facsimile or electronic signature shall be followed promptly thereafter by delivery
o f corresponding originally executed signature pages to the Court.
F.

N otice. Any and all notices, requests, consents, directives, or communications by any

party intended for any other party shall be in writing and shall, unless expressly provided otherwise
herein, be given personally, by express courier, or by postage prepaid mail, or by facsimile transmission
followed by postage prepaid mail, and shall be addressed as follows:
To Plaintiff States:
Paul Novak, Esq.
Assistant Attorney General
State o f Michigan
Consumer Protection Division, Antitrust Section
G. Mennen Williams Building
525 W est Ottawa Street
Lansing, MI 48913
Tel: 517-241-2060
Fax: 517-335-1935
To State Law Plaintiffs:
Stephen Lowey, Esq. or Richard Cohen, Esq.
Lowey Dannenberg Bemporad & Selinger, P.C.
The Gateway, 11th Floor
One North Lexington Avenue
White Plains, NY 10601
Tel: 914-997-0500
Fax: 914-997-0035
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Joseph Tabacco, Esq.
Berman DeValerio Pease Tabacco Burt & Pucillo
425 California Street
Suite 2100
San Francisco, CA 94104
Tel: 415-433-3200
Fax: 415-433-6382
To Andrx:
Louis Solomon, Esq.
Solomon Zauderer Ellenhom Frischer & Sharp
45 Rockefeller Plaza
New York, New York 10111
Tel: 212-956-3700
Fax: 212-956-4068

To Aventis:
Joseph Rebein, Esq.
Shook, Hardy & Bacon LLP
One Kansas City Place
1200 Main Street
Kansas City, Missouri 64105
Tel: 816-474-6550
Fax: 816-421-5547

Any one o f the Parties may, from time to time, change the address to which such notices, requests,
consents, directives, or communications are to be delivered, by giving the other Parties prior written
notice o f the changed address, in the manner herein above provided, ten (10) calendar days before the
change is effective.
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G.

G overning Law ; Consent to Jurisdiction. This Settlement Agreement, including, but

not limited to, the releases contained herein, shall be governed by, and construed in accordance with,
the laws o f the State o f Michigan without regard to its conflict of laws principles. The Parties to this
Settlement Agreement agree that the Final Judgment and Order shall provide that the Court shall retain
jurisdiction to enforce all provisions and terms o f this Settlement Agreement. This Settlement
Agreement shall be enforced in the United States District Court for the Eastern District of Michigan.
The Parties, on behalf of themselves and the settling members o f the Settlement Class, waive any
objection that each o f them may now have or hereafter have to the venue o f any such suit, action or
proceeding and irrevocably consent to the jurisdiction o f the Court and agree to accept and
acknowledge service in any such suit, action or proceeding.
H.

No Admission. Neither this Settlement Agreement nor any proceedings undertaken in

accordance with the terms set forth herein, shall be construed as or deemed to be evidence o f or an
admission or concession by Defendants as to the validity o f any claim that has been or could have been
asserted against them or as to any liability by them, which liability is hereby expressly denied and
disclaimed by Defendants. Neither this Settlement Agreement, nor any o f its provisions, nor any
statement or document made or filed in connection herewith, shall be filed, offered, received in evidence
or otherwise used in any action or proceeding or in any arbitration, except in connection with the
Parties’ application for approval or enforcement of this Settlement Agreement and all proceedings
incident thereto.
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I.

Return or Destruction of Discovery Materials: Resisting Disclosure Requests.

Except as otherwise provided in Section II.E o f this Settlement Agreement or as permitted by the Court
upon good cause shown (with appropriate provisions to preserve the confidentiality o f any documents
not returned to any Party):
1. within sixty (60) calendar days after the Effective Date, the Plaintiffs shall destroy or
return all materials and documents produced in these actions by any party or nonparty to the person or entity that produced those documents. Defendants may at
their discretion extend this period o f time if, within fifty-five (55) calendar days after
the Effective Date, a Plaintiff seeks such an extension in writing stating the reasons
for the delay and the time within which the return or destruction o f the documents
will be completed. In the event that any Plaintiff State is served with a freedom of
information act request, or with any subpoena or other legal process, requesting or
requiring it to provide information relating to this matter, that Plaintiff State shall act
in accordance with paragraph 13 o f the Cardizem Confidentiality Order and
paragraph 13 o f the Supplemental Confidentiality Order, each as if incorporated
herein and in effect
2. within sixty (60) calendar days after the later o f (a) the Effective Date or (b) the
termination with no right of appeal o f any litigation consolidated or coordinated with
MDL No. 1278 and the State Actions, the Defendants shall destroy or return all
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materials and documents produced in these actions by any party or non-party to the
person or entity that produced those documents.
The Parties acknowledge and agree that, pursuant to the Cardizem Protective Order, nothing in this
Settlement Agreement nor in the settlement contemplated hereby shall relieve them o f their ongoing
obligation to maintain both the confidentiality and the restrictions on use o f anything disclosed pursuant
to or in reliance upon the Cardizem Protective Order.

J.

Enforcement of Settlement Agreement and Releases. Once Effective, this

Settlement Agreement may be pleaded as a full and complete defense to any action, suit or other
proceeding that has been or may be instituted, prosecuted or attempted with respect to any o f the
Released Claims. The Parties agree that for any such proceeding, the Court or any court o f competent
jurisdiction may enter an injunction restraining prosecution o f such proceeding. The Parties further agree
that this Settlement Agreement may be pleaded as necessary for the purpose o f enforcing the Settlement
Agreement.
K.

No Penalty or Fine. The Parties agree and acknowledge that nothing paid in respect

o f the Aggregate Settlement Fund nor any other part o f this Settlement Agreement (including Rider A
hereto) constitutes or shall in any way be deemed a payment o f a penalty or a fine o f any kind.
L.

Headings. The headings used in this Settlement Agreement are intended for the

convenience o f the reader only and shall not affect the meaning or interpretation o f this Settlement
Agreement in any manner.
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IN WITNESS WHEREOF, the Parties hereto through their fully authorized representatives
have agreed to this Settlement Agreement, the attachments hereto, Rider A to this Settlement
Agreement, and the settlement embodied herein and therein, on the date first above herein written.
STATE LAW CLASS PLAINTIFFS

AVENTIS PHARM ACEUTICALS INC.

B y ;_______________________ ________
Stephen Lowey, Esq.
LOWEY DANNENBERG
BEMPORAD & SELINGER, P.C.
The Gateway, 11th Floor
One North Lexington Avenue
White Plains, NY 10601
Tel: (914)997-0500
Fax: (914) 997-0035

By:_________ ___________ ______________
Joseph Rebein, Esq.
SHOOK, HARDY & BACON L.L.P.
One Kansas City Place
1200 Main Street
Kansas City, MO 64105-2118
Tel:
(816)474-6550
Fax: (816) 421-4066

Counselfo r Defendant Aventis
Pharmaceuticals Inc.

ANDRX PHARM ACEUTICALS, INC.

B y :_______________________ ________
Joseph Tabacco, Esq.
BERMAN DEVALERIO PEASE
TABACCO BURT & PUCILLO
425 California Street
San Francisco, CA 94104
Tel: (415) 433-3200
Fax: (415) 433-6382

B y :___________ _____________ ___
Louis Solomon, Esq.
SOLOMON ZAUDERER
ELLENHORN FRISCHER &
SHARP
45 Rockefeiler Plaza
New York, NY 10111
Tel:
(212) 956-3700
Fax: (212) 956-4068

State Law Plaintiffs ’ Lead Counsel

Counselfo r Defendant Andrx
Pharmaceuticals, Inc.
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STATE LIAISON COUNSEL

CARDERM CAPITAL L.P.

B y :___________________________
Paul Novak, Esq.

B y :_________________________________
Joseph Rebein, Esq.
SHOOK, HARDY & BACON LJL.P.
One Kansas City Place
1200 M ain Street
Kansas City, MO 64105-2118
Tel:
(816)474-6550
Fax:
(816)421-4066

Assistant Attorney General
State o f Michigan
Consumer Protection Division
Antitrust Section
G. Mennen Williams Building
525 W est Ottawa Street
Lansing, MI 48913
Tel: (517) 241-2060
Fax:(517)335-1935

Counsel for Defendant Carderm
Capital L.P.
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